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Abstract 
 
G protein-coupled receptors (GPCRs) with seven -helical transmembrane domains 
receive exogenous and endogenous stimuli on the cell surface in a receptor-specific 
manner and subsequently convert them into intracellular signaling. Exogenous stimuli 
such as light, odor, taste, and pheromones come from the external environment, while 
endogenous stimuli are generated by physiologically active substances such as hormones, 
neurotransmitters, autacoids, and chemokines, which are produced within organisms. A 
huge amount of knowledge has accumulated so as to reveal that homeostasis and disease 
onset are tightly involved in the active or inactive state of the relevant GPCRs or in the 
variation in the amount of the relevant endogenous ligands. In order to improve disease 
conditions, many antagonists or agonists targeting the disease-relevant GPCRs have been 
used to treat patients. In the late 1990s, many genes with structural features similar to 
known GPCRs were identified mainly in bioinformatics studies. The identified genes 
were called orphan GPCRs, since endogenous ligands for these receptors were 
unidentified. In this study, the author focused on orphan GPCR genes, SLC-1, GPR7, and 
GPR8, and attempted to identify and characterize the endogenous ligands for these 
receptors.  
SLC-1, an orphan GPCR, with homology to the somatostatin receptor and opioid 
receptor families is expressed predominantly in the brain. Its endogenous ligand has not 
been identified. In Chapter I, the author reports the identification of melanin-
concentrating hormone (MCH) as the endogenous ligand for SLC-1 and the 
characterization of SLC-1 as a functional MCH receptor. An agonist peptide for rat SLC-
1 was purified from the rat brain and was identified as rat MCH. Synthetic MCH peptide 
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activated Gi-coupled signaling in stable Chinese hamster ovary cell lines expressing 
human and rat SLC-1, which resulted in a decrease in intracellular cAMP levels with IC50 
values in the subnanomolar range. These findings indicate that the author identified SLC-
1 as a functional MCH receptor, which has been long sought since the first discovery of 
chum salmon MCH in 1983. The results enabled the studies of MCH as a regulator of the 
energy homeostasis, anxiety, and sleep from the viewpoint of its receptor, SLC-1. 
Moreover, the pairing of SLC-1 with MCH is expected to provide helpful information to 
create screening tools for the discovery of MCH receptor antagonists. 
The structurally related orphan GPCRs, GPR7 and GPR8, present homology to the 
somatostatin receptor and opioid receptor families and are expressed in the central 
nervous system. Their endogenous ligands have not been identified. In Chapter II, the 
author reports the discovery and the characterization of a novel brain-gut peptide, 
neuropeptide W (NPW). An agonist peptide for GPR8 was purified from the porcine 
hypothalamus using stable Chinese hamster ovary cell lines expressing human GPR8, and 
a cDNA encoding its precursor protein was cloned. The cDNA encodes two forms of the 
peptide ligand with 23 and 30 amino acid residues, respectively, as mature peptides. The 
author designated the two ligands neuropeptide W-23 (NPW23) and neuropeptide W-30 
(NPW30) due to the novelty of their amino acid sequences. The amino acid sequence of 
NPW23 is identical to that of the N-terminal 23 residues of NPW30. Synthetic NPW23 
and NPW30 activated and bound to both GPR7 and GPR8 at similar effective doses. The 
enzyme-linked immunosorbent assays for NPW23 and NPW30 revealed that both 
peptides were localized in the brain, pituitary, and stomach. Intracerebroventricular 
administration of NPW23 in rats increased food intake and stimulated prolactin release. 
These findings indicate that NPW is the endogenous ligand for both GPR7 and GPR8 and 
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acts as a mediator of the central control of feeding behavior and the neuroendocrine 
system. This is the first description that the NPW molecular signaling is functioning in 
the central nervous system. 
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Abbreviations 
 
BLAST: Basic Local Alignment Search Tool 
BLASTP: Protein-protein BLAST 
CHO: Chinese hamster ovary 
CNS: Central nervous system 
ELISAs: Enzyme-linked immunosorbent assays 
GPCRs: G protein-coupled receptors 
GTPS: Guanosine-5′-O-(3-thio)triphosphate 
HPLC: High performance liquid chromatography 
MCH: Melanin-concentrating hormone 
NPW: Neuropeptide W 
NPW23: Neuropeptide W-23 
NPW30: Neuropeptide W-30 
PBS: Phosphate-buffered saline 
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General Introduction 
 
G protein-coupled receptors (GPCRs) belong to the largest family of cell surface 
receptors with a unique structural feature of seven -helical transmembrane domains, 
which are associated with heterotrimeric G proteins (Rosenbaum et al., 2009). The 
number of human GPCRs is estimated to be about 800 to date (Isberg et al., 2015). GPCRs 
are stimulated by binding to extracellular signal transducing molecules such as hormones, 
neurotransmitters, autacoids, chemokines, tastes, and odors, and subsequently change 
their conformation to generate a signal via activation of the GPCR-interacted molecules 
inside the cells (Selbie and Hill, 1998). An approach to isolate the receptor genes for 
already-known bioactive molecules, also called endogenous ligands because they are 
synthetized within organisms, allowed the pairing of bioactive molecules with previously 
unknown receptors through the early 1990s (Masu et al., 1987; Arai et al., 1990; Honda 
et al., 1991; Hirata et al., 1991; Masu et al., 1991; Sasaki et al., 1991).  
GPCRs have various physiological roles in the human body. Homeostasis of the human 
body is controlled by the fine tuning of GPCRs, and state of the GPCRs is adjusted by 
adequate amounts of their respective endogenous ligands such as dopamine and orexin in 
the central nervous system (CNS), adrenaline and angiotensin II in the cardiovascular 
system, histamine and glucagon-like peptide 1 in the digestive system, and gonadotropin-
releasing hormone, follicle-stimulating hormone, and luteinizing hormone in the 
reproductive system. Thus, excess and lack of signaling via GPCRs cause diseases. In 
order to relieve the disease conditions by drug treatment, antagonists or agonists of 
disease-relevant GPCRs have been developed, and, historically, many drugs with better 
efficacy and safety have been used for the treatment of patients in almost all disease areas. 
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GPCRs have become a major drug target class so that about 30% of the drugs in the 
market act on GPCR molecules (Overington et al., 2006).  
In the late 1990s, many genes with structural features similar to known GPCRs were 
isolated with the assistance of bioinformatics studies of the whole genome sequence and 
a variety of cDNA sequence data sets in several organisms (Wilson et al., 1998). The 
isolated genes were called orphan GPCRs. Since the genes were defined only by their 
sequences with the characteristic features of seven -helical transmembrane domains and 
specific motifs of GPCRs (Wess, 1998; Fredriksson et al., 2003; Rovati et al., 2007), the 
presence of the endogenous ligands for the orphan GPCRs remained unknown. Besides, 
no one could predict which orphan GPCR gene was correctly translated as a GPCR 
protein and which orphan GPCR protein could be paired with unidentified endogenous 
ligands. 
The presence of orphan GPCR genes in mammalian genomes provided the 
opportunities to initiate a distinct field of GPCR research called reverse pharmacology. 
Studies proceed in the following order: selection of the prioritized genes from many 
orphan GPCR genes, identification of the endogenous ligand for the selected orphan 
GPCR, estimation of the pathophysiological significance of the identified endogenous 
ligand, screening and chemical optimization of compounds as antagonists or agonists 
acting on the deorphanized GPCR, assessment of the compound efficacy in vivo using 
animal models followed by safety tests, and clinical trials for evaluating efficacy and 
safety in humans (Libert et al., 1991; Kotarsky and Nilsson, 2004). According to the 
concept of reverse pharmacology, a limited number of research groups reported 
deorphanization of orphan GPCRs, discovery of novel endogenous peptide ligands, and 
pioneering work on the biological functions of the identified endogenous ligands and 
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deorphanized GPCRs (Meunier et al., 1995; Reinscheid et al., 1995; Hinuma et al., 1998; 
Sakurai et al., 1998). Reverse pharmacology has great potential to elucidate the 
mechanism of unknown biological phenomena, which can be explained by the pairing of 
newly identified endogenous ligands and their deorphanized GPCRs. Additionally, it 
provides opportunities to identify entirely new biological phenomena caused by the pairs. 
Besides, as far as pathophysiological meanings of the pairs are verified, drug discovery 
efforts are implemented to create antagonists or agonists acting on the deorphanized 
GPCR.  
The author decided to use the reverse pharmacology approach to identify endogenous 
ligands for the orphan GPCRs followed by molecular, cellular, and in vivo analysis of the 
biological functions of the identified endogenous ligands and the deorphanized GPCRs. 
The limited number of success noted above prompted us to refine each experimental step 
needed in the course of deorphanization. There were four imperative steps for 
deorphanization as follows: prioritization of orphan GPCRs applied to the assay, 
establishment of cell lines expressing the orphan GPCR gene in sufficient amounts, 
establishment of the assays dealing with any types of ligand-induced GPCR signaling, 
and composition of the ligand bank tested in the assay.  
In this study, the author aimed to obtain useful knowledge in the fields of basic science 
and drug discovery by deorphanization of orphan GPCRs, which was followed by 
characterization of the relevant molecules. In Chapter I, the author created experimental 
systems focused on deorphanization of the orphan GPCRs with unidentified endogenous 
peptide ligands and applied them to identify melanin-concentrating hormone (MCH) as 
the endogenous ligand for SLC-1. Characterization of SLC-1 as a functional MCH 
receptor was conducted. In Chapter II, the author discovered a novel brain-gut peptide, 
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neuropeptide W (NPW), as the endogenous ligand for GPR7 and GPR8. Studies on 
molecular biology, in vitro pharmacology, and tissue distribution of NPW were conducted. 
In addition, an exploratory study on the in vivo effects of NPW was conducted to estimate 
NPW biological role. 
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Chapter I: Discovery and Analysis of Melanin-
concentrating Hormone as the Specific Ligand for the 
Orphan GPCR, SLC-1 
 
1. Introduction 
A DNA clone of SLC-1 was originally isolated by Kolakowski et al. from a human 
genomic DNA library (Kolakowski et al., 1996) and was suggested to encode an orphan 
GPCR with higher amino acid sequence similarity to the seven transmembrane regions 
of the five subtypes of the somatostatin receptor and the three subtypes of the opioid 
receptor (about 40% amino acid identity). SLC-1 mRNA is expressed in the forebrain and 
hypothalamus in humans and in the brain, heart, kidney, and ovary in rats (Kolakowski et 
al., 1996). Two years later, a cDNA clone of the rat orthologue of SLC-1 was 
independently isolated by screening of a rat brain cDNA library with a hybridization 
probe whose nucleotide sequence was derived from PCR using a set of degenerate primers 
of each of the third and seventh transmembrane of known GPCRs (Lakaye et al., 1998). 
Comparison of the deduced amino acid sequences between the two revealed that the 
human SLC-1 DNA could not encode the full human SLC-1 protein due to the insertion 
of an intron sequence into the 5-region of the human SLC-1 DNA. 
In Chapter I, the author reports the purification and characterization of MCH. An 
agonist peptide for rat SLC-1 was purified from the rat brain and was identified as rat 
MCH peptide. The functional characterization of MCH for human and rat SLC-1 
indicated that MCH is the endogenous ligand for SLC-1. 
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2.  Materials and Methods 
2.1. Establishment of Chinese hamster ovary (CHO) cell lines expressing rat SLC-
1 
A cDNA encoding rat SLC-1 (Lakaye et al., 1998) was isolated by PCR from the reverse-
transcribed product of poly (A) RNA of the rat whole brain (CLONTECH). Two PCR 
primers were designed to clone a rat cDNA with a SalI cleavage site and a SpeI cleavage 
site that were located at the 5`- and 3`-ends, respectively. The two primer sequences were 
as follows: 5`-GTCGACATGGATCTGCAAACCTCGTTGCTGTG-3` (forward) and 5`-
ACTAGTTCAGGTGCCTTTGCTTTCTGTCCTCT-3` (reverse). The SalI- and SpeI-
digested fragment of the rat cDNA was ligated into a unique site of the pAKKO-111H 
expression vector (Hinuma et al., 1994), which equipped the SR promoter and dhfr gene 
as the selection marker. CHO dhfr− cells were transfected with the expression vector by 
calcium phosphate method using a CellPhect transfection kit (Amersham Pharmacia 
Biotech). CHO cell lines stably expressing the rat SLC-1 were selected under conditions 
wherein the growth medium lacked nucleotides. 
 
2.2. Cloning of human SLC-1 cDNA 
A cDNA encoding human SLC-1 was isolated from a cDNA library constructed from a 
human embryonic brain extract (Gibco BRL) using a gene-trapper method according to 
the supplier’s protocol (GeneTrapper cDNA Positive Selection System, Gibco BRL). The 
gene-trapper method employed two oligonucleotides whose sequences were identical to 
the nucleotide sequences found in a human genomic SLC-1 DNA clone (Kolakowski et 
al., 1996): 5`-CAACAGCTGCCTCAACCC-3` and 5`-CCTGGTGATCTGCCTCCT-3`. 
The former oligonucleotide was biotinylated and was employed for hybridization, and the 
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latter was used to synthesize double-stranded DNA. An isolated cDNA was sequenced by 
an ABI PRISM 377 DNA sequencer (PE Applied Biosystems) using a DyeDeoxy 
Terminator Cycle Sequence Kit (PE Applied Biosystems). 
 
2.3. Establishment of CHO cell lines expressing human SLC-1 
CHO cell lines expressing human SLC-1 were prepared by using two different expression 
vectors. A human SLC-1 nucleotide starting at the 1st ATG codon and ending at the stop 
codon in the cloned human SLC-1 cDNA was named human SLC-1 (L), while a human 
SLC-1 nucleotide starting at the 3rd ATG codon and ending at the stop codon in the cloned 
human SLC-1 cDNA was named human SLC-1 (S). The human SLC-1 (L) DNA with a 
SalI cleavage site at the 5`-end and a SpeI cleavage site at the 3`-ends was obtained by 
PCR from the cloned human SLC-1 cDNA as a template using two primers: 5`-
AGTCGACATGTCAGTGGGAGCCATGAAGAAGAAGGG-3` (forward) and 5`-
AACTAGTTCAGGTGCCTTTGCTTTCTGTCCTCT-3` (reverse). In the same way, the 
human SLC-1 (S) DNA with a SalI cleavage site at the 5`-end and a SpeI cleavage site at 
the 3`-ends was obtained by PCR from the cloned human SLC-1 cDNA as a template 
using two primers: 5`-GTCGACATGGACCTGGAAGCCTCGCTGCTGC-3` (forward) 
and 5`-ACTAGTTCAGGTGCCTTTGCTTTCTGTCCTC-3` (reverse). Each SalI- and 
SpeI-digested fragment obtained from the PCR-amplified human SLC-1 (L) DNA and 
human SLC-1 (S) DNA was ligated into a unique site of the pAKKO-111H expression 
vector. CHO dhfr− cells were transfected with the expression vector by calcium phosphate 
method using a CellPhect transfection kit (Amersham Pharmacia Biotech). CHO cell lines 
stably expressing the human SLC-1 (L) and the human SLC-1 (S) were selected under 
conditions wherein the growth medium lacked nucleotides. 
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2.4. Phylogenetic analysis of the GPCRs structurally similar to rat SLC-1 protein 
One algorithm in Basic Local Alignment Search Tool (BLAST) programs, a protein-
protein BLAST (BLASTP) search was conducted using the amino acid sequence of rat 
SLC-1 as a query against the database Non-redundant protein sequences (nr) of National 
Center for Biotechnology Information (NCBI). Amino acid sequences of human GPCRs 
were chosen from the search result in order of similarity to the rat SLC-1 by an index of 
Max score. Twelve GPCRs selected by the similarity were as follows: melanin-
concentrating hormone receptor 1 (NP_005288), somatostatin receptor type 1 
(NP_001040), somatostatin receptor type 2 (NP_001041), somatostatin receptor type 3 
(NP_001042), somatostatin receptor type 4 (NP_001043), somatostatin receptor type 5 
(NP_001044), mu-type opioid receptor isoform MOR-1 (NP_000905), delta-type opioid 
receptor (NP_000902), kappa-type opioid receptor isoform 1 (NP_000903), nociceptin 
receptor (NP_001186948), neuropeptides B/W receptor type 1 (NP_005276), and 
neuropeptides B/W receptor type 2 (NP_005277). When the author started the study in 
1998, three GPCRs, melanin-concentrating hormone receptor 1, neuropeptides B/W 
receptor type 1, and neuropeptides B/W receptor type 2 were orphan GPCRs with 
unknown endogenous ligands, and were called SLC-1, GPR7, and GPR8, respectively. A 
phylogenetic tree was constructed among the 12 GPCRs and the rat SLC-1 by using the 
neighbor-joining method. 
 
2.5. Northern blot analysis of SLC-1 in human tissues 
Northern blot experiment was conducted essentially as described (Ogi et al., 1990) with 
following minor modifications. The cloned human SLC-1 cDNA was used as a template 
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to synthesize DNA probes that were labeled with [-32P]dCTP (Dupont/NEN) by a multi 
prime DNA labeling kit (Amersham Pharmacia Biotech). Human Multiple Tissue 
Northern Blots membranes (CLONTECH) were hybridized with the radiolabeled probes 
in hybridization buffer (2  SSC, 0.1 % SDS, 10  Denhardt’s Solution, 50 % formamide) 
for an overnight incubation at 42°C. The Human Multiple Tissue Northern Blots were 
premade membranes: poly (A) RNA samples purified from a variety of human tissues 
were electrophoresed, and then these separated RNA molecules in the gel were transferred 
to nylon membranes. After the hybridization, the membrane filters were finally washed 
in 0.1 % SSC with 0.1 % SDS at 50°C. Signals of the radiolabeled probes that bound to 
human SLC-1 mRNA were detected by a Bioimageanalyzer-BAS2000 (Fuji Film). 
 
2.6. Assay for inhibition of forskolin-induced intracellular accumulation of cAMP 
Inhibitory activities of test samples for cAMP accumulation were measured. Cell lines of 
CHO expressing rat SLC-1 (CHO-rat SLC-1) were plated on 24-well plates at 5  104 
cells/well and were cultured for 2 days. The cells were washed three times with 0.5 ml of 
assay buffer (Hanks’ buffered salt solution supplemented with 0.2 mM 3-isobutyl-1-
methylxantine (Wako Pure Chemical), 0.05% bovine serum albumin, and 20 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)) and were cultured in the assay 
buffer for 30 min. After washing the cells three times with 0.5 ml of the assay buffer, a 
test sample in 0.5 ml of the assay buffer supplemented with 1 M forskolin (Wako Pure 
Chemical) was added to the cells in each well, and the cells were incubated at 37°C for 
24 min. cAMP synthesis in the cells was terminated by addition of 0.1 ml of 20% 
perchloric acid, and intracellular cAMP was extracted with 20% perchloric acid on ice 
for 1 h. The amount of extracted cAMP was measured using an enzyme-linked 
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immunoassay kit (Amersham Pharmacia Biotech). The same procedure was used for 
assessing the agonist activity of MCH on the cell lines of CHO expressing human SLC-
1 (L) (CHO-human SLC-1 (L)) and CHO expressing human SLC-1 (S) (CHO-human 
SLC-1 (S)). 
 
2.7. Purification of MCH as an endogenous ligand for SLC-1 from the rat brain 
The brain tissues of 70 male Wistar rats (8 weeks old) were dissected and were boiled in 
800 ml of pure water for 10 min, immediately after decapitation. After cooling with ice, 
acetic acid was added to make a 1.0 M solution, and the tissue was homogenized using a 
Polytron homogenizer. The homogenate was centrifuged, and a double volume of acetone 
was added to supernatant. The precipitates were re-extracted with 800 ml of 1.0 M acetic 
acid and were processed in a similar fashion. The acetone-treated extract was centrifuged 
to remove the pellets. The supernatant was concentrated to remove the acetone and was 
then extracted with diethyl ether to remove lipid. The solution was applied to an YMCgel 
ODS-AM 120-S50 column (30.0  240 mm; YMC), and the column was eluted with 60% 
acetonitrile (CH3CN) in 0.1% trifluoroacetic acid. The eluate was lyophilized, and the 
lyophilized powder dissolved in 1.0 M acetic acid was charged on a SP-Sephadex C-25 
column (25.0  80 mm; Amersham Pharmacia Biotech). The column was then eluted with 
1.0 M acetic acid, 2.0 M pyridine, and 2.0 M pyridine-acetic acid (pH 5), successively. 
The 2.0 M pyridine-acetic acid fraction was lyophilized. An agonist peptide for rat SLC-
1 was purified from the lyophilized materials by successive high performance liquid 
chromatography (HPLC) using a TSKgel ODS-80TS column (21.5  300 mm; 10–60% 
CH3CN gradient in 0.1% trifluoroacetic acid for 80 min at 5.0 ml/min; Tosoh), a CM-
2SW column (4.6  150 mm; 10–500 mM ammonium formate (HCOONH4) (pH 5.25) 
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gradient in 10% CH3CN for 60 min at 1.0 ml/min; Tosoh), a diphenyl column of Vydac 
219-TP54 (4.6  250 mm; 27.5–42.5% CH3CN gradient in 0.1% trifluoroacetic acid for 
90 min at 1.0 ml/min; Separation Group), and a Develosil ODS-UG-3 column (2.0  150 
mm; 27.5–42.5% CH3CN gradient in 0.1% trifluoroacetic acid for 120 min at 0.2 ml/min; 
Nomura Kagaku) combined with the assay for inhibition of forskolin-induced 
intracellular accumulation of cAMP in CHO-rat SLC-1 cells. The activity was recovered 
as a single peak at 36.8% of CH3CN in the final HPLC. 
 
2.8. Structural analysis of the purified peptide 
The N-terminal amino acid sequence of the purified peptide was determined using two 
protein sequencers, Beckman LF3400 (Beckman Instruments, Inc.) and Procise 491cLC 
(Applied Biosystems, Inc.). The sequencing reaction by the Beckman LF3400 converts 
Cys to dehydroalanine, and the resulting phenylthiohydantoin (PTH) derivative is 
detected as PTH-dehydroalanine. The Procise 491cLC analysis provides amino terminal 
amino acid sequence information based on a conventional method of the Edman 
degradation. The mass spectrum of the purified peptide was measured using a JEOL HX-
110 (Jeol Ltd., Tokyo, Japan) equipped with a Cs gun for the LSIMS mode. 
 
2.9. Peptide 
Human melanin-concentrating hormone, rat somatostatin-14, rat somatostatin-28, and rat 
cortistatin-29 were purchased from Peninsula Laboratories Ltd. 
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3.  Results 
3.1. Structural and gene expression features of SLC-1 
SLC-1 protein showed sequence similarity to other human GPCRs with known or 
unknown endogenous ligands. Twelve GPCRs selected by a BLASTP search against a 
non-redundant protein database in order of similarity to the rat SLC-1 were as follows: 
human orthologue of the rat SLC-1, five subtypes of the somatostatin receptor, three 
subtypes of the opioid receptor, one opioid-like receptor, and two structurally related 
orphan GPCRs, GPR7 and GPR8 (O'Dowd et al., 1995). The author attempted to clarify 
an evolutionary relationship among the selected twelve human GPCRs above and the rat 
SLC-1 by the neighbor-joining method. The phylogenetic tree demonstrated that SLC-1 
presented homology to the somatostatin receptor and opioid receptor families (Fig. 1-1).  
The gene expression pattern of SLC-1 in human tissues was examined by northern blot. 
Human SLC-1 was expressed predominantly in the brain and moderately in the ovary and 
spinal cord (Fig. 1-2). Gene expression of human SLC-1 was not detected in nearly all 
peripheral tissues, except the ovary. 
 
3.2. Technologies specializing in the identification of the endogenous peptide 
ligands for orphan GPCRs 
The author decided to focus on research of the orphan GPCRs with the likelihood of 
presenting bioactive peptides as their endogenous ligands. This strategy required a set of 
technologies that could be matched with an efficient detection of peptide agonist-induced 
activation of the orphan GPCRs in cell- or membrane-based assays. Expression levels of 
the transfected-orphan GPCR genes in the assay cell lines were some of the critical factors 
to ensure the robustness of the assay results. The cell lines were established by screening 
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based on the expression levels of the orphan GPCR gene, which were measured 
quantitatively (Fig. 1-3A). The next challenge was about the test samples to be examined 
in the assays. To increase the probability of detecting the agonist activities of peptide 
substances, the test samples were prepared from a wide variety of animal organs through 
a peptide-selective extraction and fractionation by reverse phase HPLC (Fig. 1-3B). The 
remaining challenge was what assay should be used in the experiments, since no one 
knew which subtype of  subunit of G protein was actually coupled with the orphan 
GPCR of my interests. Multiple assays were applied to detect a variety of intracellular 
signals that were generated in the assay cell lines: an assay for Gs-mediated intracellular 
cAMP synthesis, an assay for Gi-mediated inhibition of forskolin-induced intracellular 
accumulation of cAMP, and an assay for Gq-mediated arachidonic acid metabolite release. 
In addition to these assay systems, [35S] guanosine-5′-O-(3-thio)triphosphate  (GTPS) 
binding to an activated form of G protein subunit  in the membranes of the cell lines 
was determined (Fig. 1-3C). 
 
3.3. Isolation and identification of MCH as the endogenous ligand for rat SLC-1 
The author purified an agonist peptide for rat SLC-1 from the rat brain using CHO-rat 
SLC-1 cells and demonstrated that the structure of the agonist peptide was identical to 
that of rat MCH. In the assays of intracellular signaling evoked by peptide fractions 
prepared from a variety of tissue extracts, the fractions from the rat whole brain, porcine 
whole brain, and porcine hypothalamus stimulated the inhibition of forskolin-induced 
intracellular accumulation of cAMP in the CHO-rat SLC-1 cells. Their activities were 
sensitive to incubation with proteinase (data not shown). Since the rat whole brain fraction 
presented the highest agonist activity per tissue weight among all extracts, extracts of the 
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rat brain were subjected to purification of an agonist substance for rat SLC-1 by 
successive chromatography. Its activity was assessed using the cAMP accumulation 
inhibition assay (Fig.1-4 A and B). The purification process yielded approximately 950 
pmol of the purified agonist peptide for rat SLC-1 from 140 g of the rat brain (Fig. 1-5). 
The purified peptide was subjected to N-terminal amino acid sequence analysis using two 
protein sequencers, and the analysis afforded the following sequence, 
DFDMLRCMLGRVYRPC, corresponding to the 1st to 16th residues of rat MCH (Table 
1-1). The Cys residues at the 7th and 16th positions were identified as PTH-dehydroalanine. 
Mass spectrum analysis using LSIMS of the active substance provided the protonated 
molecular ion peak at m/z 2387.2 (Fig. 1-6), which represented the whole sequence of rat 
MCH with 19 amino acid residues. Consequently, the amino acid sequence of the purified 
agonist peptide was determined to be DFDMLRCMLGRVYRPCWQV, and the agonist 
peptide for rat SLC-1 was identified as rat MCH. 
 
3.4. Comparison of SLC-1 amino acid sequences among humans, rats, and mice 
The author compared SLC-1 amino acid sequences of humans, rats, and mice. The longest 
open reading frame of human (Fig. 1-7), rat, and mouse SLC-1 nucleotide sequences 
encode SLC-1 proteins composed of 422, 353, and 353 amino acid residues, respectively. 
The deduced amino acid sequences of human, rat, and mouse SLC-1 demonstrated 
structural features common to the rhodopsin family of GPCRs (Fig. 1-8). The respective 
three SLC-1 proteins possess seven membrane-spanning domains with potentially 
extracellular and cytoplasmic terminus, the E/DRY motif on TM3 (Rovati et al., 2007), 
and the NPXXY motif at the cytoplasmic end of TM7 (Fritze et al., 2003). The sequence 
alignment indicated that the 353-amino acid sequence of human SLC-1 starting with 
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Met70 and ending with Thr422 was nearly identical to the whole sequences of the rat and 
mouse SLC-1. The human SLC-1 protein of 353 amino acid residues was renamed human 
SLC-1 (S), while the human SLC-1 protein of 422 amino acid residues was renamed 
human SLC-1 (L). The human SLC-1 (S), the rat SLC-1, and the mouse SLC-1 shared 
95.8% amino acid identity. The difference in amino acid length between the human SLC-
1 (L) and the other SLC-1 results from its N-terminal region with an addition of 69 amino 
acids, which includes two Met residues, potential translation start sites, at positions 1 and 
6. 
 
3.5. Inhibition of intracellular cAMP accumulation by MCH in CHO cells 
expressing SLC-1 
The author examined the functional activities of MCH on three different CHO cells 
expressing the human SLC-1 (S), the human SLC-1 (L), and the rat SLC-1, respectively. 
Amino acid sequences of human MCH and rat MCH are entirely identical to each other, 
and, thus, the synthetic human MCH peptide was used to assess the inhibition of 
intracellular cAMP accumulation. The MCH peptide inhibited cAMP accumulation in a 
dose-dependent manner in cell lines of CHO expressing human SLC-1 (L) (CHO-human 
SLC-1 (L)), CHO expressing human SLC-1 (S) (CHO-human SLC-1 (S)), and CHO 
expressing rat SLC-1 (CHO-rat SLC-1), but not in the CHO-mock cells that were 
established by the transfection of the pAKKO-111H vector without any inserts (Fig. 1-
9A). MCH inhibited cAMP accumulation in both the CHO-human SLC-1 (S) and the 
CHO-rat SLC-1 cells with IC50 values of 0.08 nM and 0.1 nM, respectively. On the other 
hand, MCH only weakly inhibited the accumulation of cAMP in the CHO-human SLC-1 
(L) cells with an IC50 value of 5 nM.  
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The author then assessed the potential of agonist peptides for the somatostatin receptor 
family, which showed homology with the rat and human SLC-1 based on my search for 
GPCRs with known endogenous ligands to inhibit intracellular cAMP accumulation in 
cell lines expressing SLC-1. The peptides, somatostatin-14, somatostatin-28, and 
cortistatin-29, are endogenous ligands for the five subtypes of the somatostatin receptor. 
The three peptides at the concentration of 1 M did not inhibit cAMP accumulation in the 
CHO-rat SLC-1 cells (Fig. 1-9B). 
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4.  Discussion 
In this study, the author adopted a strategy to identify the endogenous ligands for orphan 
GPCRs with significant structural similarities to the GPCRs whose endogenous ligands 
had been known as peptides, but not as small molecular weight substances such as lipids, 
phospholipids, amines, nucleotides, amino-acid derivatives, prostanoids, or leukotrienes. 
In line with this strategy, experimental systems to detect agonist activities to GPCRs were 
developed so that subtle changes induced by the peptide-focused natural substances could 
be monitored accurately in the cell- or membrane-based GPCR-mediated signaling assays 
(Fig. 1-3C). These experimental systems were used to identify an endogenous peptide 
ligand for SLC-1, an orphan GPCR showing high amino acid sequence similarities to the 
somatostatin receptor and opioid receptor families (Fig. 1-1). The author purified rat 
MCH as the agonist peptide for SLC-1 from the rat brain using the CHO-rat SLC-1 cells 
(Fig. 1-5). This finding indicates the creation of an experimental platform for 
deorphanization of orphan GPCRs, which enabled the identification of MCH as the 
endogenous ligand for SLC-1. 
The author demonstrated that MCH specifically inhibited forskolin-induced 
intracellular cAMP accumulation in a dose-dependent manner in CHO cells expressing 
the human SLC-1 (S), the human SLC-1 (L), and the rat SLC-1, with IC50 values of 0.08 
nM, 5 nM, and 0.1 nM, respectively (Fig. 1-9A). MCH showed high agonist potency to 
the CHO cells expressing the human SLC-1 (S) and the rat SLC-1, but not to the CHO 
cells expressing the human SLC-1 (L). Human SLC-1 (L) is supposed to be a protein of 
422 amino acid residues, which is translated from the 1st AUG start codon of the human 
SLC-1 mRNA, while human SLC-1 (S) is supposed to be a protein of 353 amino acid 
residues, which is translated from the 3rd AUG start codon of the mRNA (Fig. 1-7). The 
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human SLC-1 (S) resembles the rat SLC-1 with 95.8 % amino acid identity (Fig. 1-8). 
The weak responsiveness of the putative human SLC-1 (L) to the MCH stimulation in the 
CHO cells can be explained that the extra N-terminal portion confers conformational 
changes of the human SLC-1 (L), which leads to a lower affinity for MCH or an inefficient 
G protein activation inside the cells. The difference in the responsiveness to the MCH 
stimulation between the human SLC-1 (L) and the human SLC-1 (S) does not necessarily 
mean that an authentic human SLC-1 protein is not produced from the human SLC-1 
mRNA in vivo, because the protein translation machinery might differ between an 
artificial protein expression system using CHO cells and in vivo. Based on the 
experimental results in this study, it is postulated that the authentic human SLC-1 protein 
with an efficient signal transduction can be successfully produced in the tissues such as 
the brain where the human SLC-1 mRNA is predominantly expressed in vivo (Fig. 1-2). 
The gene expression profile of human SLC-1 coincides with the experimental results 
about the tissue distribution of MCH peptide, which demonstrated that the 
immunoreactive MCH is mainly localized in the brain (Takahashi et al., 1995). These 
results support the idea that MCH primarily functions in the brain as a neurotransmitter 
via the activation of SLC-1. These findings indicate that SLC-1 gene encodes a functional 
MCH receptor that signals through inhibition of intracellular cAMP synthesis. 
The author identified SLC-1 as a MCH receptor in 1999 (Shimomura et al., 1999). The 
molecular nature of a functional MCH receptor had been unknown until 1999 when five 
research groups, including us, independently reported that MCH is the endogenous ligand 
for SLC-1 (Chambers et al., 1999; Saito et al., 1999; Shimomura et al., 1999; Bächner et 
al., 1999; Lembo et al., 1999). The following is the brief description of advancements in 
the research of MCH from the discovery to the studies of biological functions until 1998. 
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MCH was first discovered from piscine pituitaries as a fish skin-color regulating hormone, 
which stimulates the perinuclear aggregation of melanosomes within teleost melanocytes 
in 1983 (Kawauchi et al., 1983). Since the existence of the MCH-like immunoreactivity 
in the rat brain was reported in 1986 (Zamir et al., 1986; Naito et al., 1986), much attention 
has been paid on the studies of its molecular structure and biological functions in 
mammalian organisms. In addition to the structural analysis of rat MCH peptide isolated 
from the hypothalamus (Vaughan et al., 1989), molecular cloning of human, rat, and 
mouse MCH precursor genes revealed that each mature peptide is a 19-amino acid cyclic 
peptide with entirely identical amino acid sequences (Nahon et al., 1989; Presse et al., 
1990; Breton et al., 1994). In the rat brain, MCH-positive perikarya were found 
exclusively in the lateral hypothalamus area and zona incerta, which are involved in the 
regulation of feeding behavior. MCH fibers are widely distributed through the brain 
(Bittencourt et al., 1992), suggesting that MCH may act as a neurotransmitter involved in 
a wide range of physiological functions in the CNS. Qu et al. reported in 1996 that Pmch 
mRNA expression levels in the hypothalamus positively correlated with food intake in 
the ob/ob mice and fasting mice models compared to control mice, and that MCH 
injection into the lateral ventricles of rats resulted in increased food consumption (Qu et 
al., 1996). An experiment using genetically modified mice with null mutation of the Pmch 
gene that was reported in 1998 suggested a role of MCH as an orexigenic peptide acting 
in the hypothalamus, which was drawn by the facts that the mice showed phenotypes of 
leanness with hypophagia and an increased metabolic rate (Shimada et al., 1998). As a 
considerable number of useful knowledge about MCH biology had accumulated from the 
identification of MCH from chum salmon in 1983 through the year of 1998, discovery of 
a MCH receptor became an urgent challenge to deepen the understanding of the molecular 
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mechanism at the site of action of MCH. Thus, the discovery of SLC-1 as a MCH receptor 
impacted on the research of MCH biology together with the other four groups in 1999. 
Furthermore, the identification and understanding of SLC-1 advanced our knowledge 
on MCH. In 2001, the second MCH receptor presenting an amino acid identity of 36% 
with SLC-1 was reported by six groups, including us (Hill et al., 2001; Mori et al., 2001; 
Sailer et al., 2001; An et al., 2001; Wang et al., 2001; Rodriguez et al., 2001). The second 
MCH receptor exists in humans, monkeys, and dogs, but not in rodents. As a consequence 
of the full characterization of the endogenous ligand for SLC-1 and the second MCH 
receptor, the International Union of Basic and Clinical Pharmacology officially named 
SLC-1 and the second MCH receptor, melanin-concentrating hormone receptor 1 
(MCHR1) and melanin-concentrating hormone receptor 2 (MCHR2), respectively (Foord 
et al., 2005). Studies using the mice with null mutation of the Mchr1 that was formerly 
called Slc-1 clarified the role of MCH in energy homeostasis as the Mchr1 KO mice were 
resistant to diet-induced obesity with higher metabolic rates (Marsh et al., 2002; Chen et 
al., 2002). In vitro MCHR1 pharmacology was developed to carry out pharmacological 
evaluation of small molecule compounds as MCHR1 antagonists. In the recombinant cells 
expressing MCHR1, MCH stimulates Gi- and Gq-coupled signaling pathways (Hawes et 
al., 2000). Besides, MCH derivatives with high affinity binding to MCHR1 and less non-
specific binding were newly synthesized to establish reliable receptor binding assays 
(Audinot et al., 2001; Takekawa et al., 2002; Gao et al., 2004). A non-peptide MCHR1 
antagonist, T-226296, effective in a rat model of food intake was reported as a candidate 
compound for anti-obesity treatment by a group in our research laboratories in 2002 
(Takekawa et al., 2002). Since then, different companies published a number of studies 
and patents concerning the medicinal chemistry of MCHR1 antagonists (Johansson, 
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2011). Additionally, several compounds have entered clinical trials with the indication of 
obesity treatment (MacNeil, 2013). In addition to MCH biological role in energy 
homeostasis, the distribution pattern of MCH fibers throughout the brain triggered the 
studies on other physiological functions in the CNS such as anxiety (Smith et al., 2006), 
depression (Saito et al., 2001), and sleep (Verret et al., 2003). Small molecule MCHR1 
antagonists and genetically modified mice with mutations in the Mchr1 gene have been 
utilized to unravel the involvement of MCH in the regulation of anxiety (Borowsky et al., 
2002; Chaki et al., 2005), depression (Borowsky et al., 2002; Chaki et al., 2005), and 
sleep (Adamantidis et al., 2008; Willie et al., 2008).  
In conclusion, the author identified MCH as the endogenous ligand for SLC-1. The 
discovery of SLC-1 as a functional MCH receptor will provide new insights into the 
physiological roles of MCH and its receptor, SLC-1, and will enable the development of 
MCH receptor modulators for the treatment of CNS diseases. 
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5. Tables 
 
 
 
Table 1-1 
N-terminal amino acid sequence analysis of an agonist peptide for rat SLC-1 
The N-terminal amino acid sequence of the agonist peptide was determined by two 
independent experiments named Procise 491cLC analysis and LF 3400 analysis. The 
Procise 491cLC analysis provided N-terminal amino acid sequence information based on 
a conventional method of the Edman degradation. Cysteine residue in the peptide was 
detected as a stable derivative of PTH-dehydroalanine in the LF 3400 analysis. 
 
  
Cycle Procise 491cLC analysis LF 3400 analysis
1 Asp (1.95) Asp (20.7)
2 Phe (2.18) Phe (12.7)
3 Asp (2.05) Asp (17.2)
4 Met (2.16) Met (13.5)
5 Leu (1.92) Leu (10.6)
6 Arg (1.38) Arg (11.7)
7 not detected PTH-dehydroalanine
8 Met (1.67) Met (13.1)
9 Leu (1.55) Leu (9.0)
10 Gly (1.05) Gly (8.2)
11 Arg (1.09) Arg (4.9)
12 Val (1.34) Val (10.1)
13 Tyr (1.25) Tyr (8.9)
14 Arg (0.91) not detected
15 Pro (0.57) Pro (7.9)
16 not detected PTH-dehydroalanine
17 Trp (0.35) not detected
18 Gln (0.28) not detected
19 Val (0.05) not detected
Detected amino acid (pmol)
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6. Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1-1. A phylogenetic tree of GPCRs with high similarity to SLC-1 protein. 
Selected GPCRs presenting amino acid sequence similarity to rat SLC-1 were analyzed 
by the neighbor-joining method. Bootstrap values are placed on each node. Three GPCRs, 
GPR7, GPR8, and SLC-1, were recognized as orphan GPCRs, and the others were GPCRs 
with known endogenous peptide ligands when the study in Chapter I started. Sst1 receptor, 
somatostatin receptor 1; sst4 receptor, somatostatin receptor 4; sst2 receptor, somatostatin 
receptor 2; sst3 receptor, somatostatin receptor 3; sst5 receptor, somatostatin receptor 5; 
NOP receptor, nociceptin receptor;  receptor, kappa-type opioid receptor isoform 1;  
receptor, delta-type opioid receptor;  receptor, mu-type opioid receptor isoform MOR-
1. 
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Fig. 1-2. Gene expression profile of human SLC-1. SLC-1 mRNA expression levels in 
various human tissues were analyzed by northern blot. Premade membranes (Human 
Multiple Tissue Northern Blot, CLONTECH) ready to be hybridized were used. Upper 
lane indicates name of each tissue from which poly (A) RNA sample was purified for 
creation of the premade membranes. 
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Fig. 1-3. Essential steps to be refined for successful deorphanization. A, establishment 
of orphan GPCR gene-transfected cell lines. The cell lines expressing orphan GPCR gene 
at the highest level were selected by a quantitative measurement of its mRNA. B, peptide 
bank. Test samples focused on peptide substances were obtained from extracts of fresh 
animal tissues followed by reverse phase HPLC. C, assay package. Multiple assays were 
used to detect agonist activities of ligand (L) for the orphan GPCR gene-transfected cell 
lines. 
  
A 
B 
C 
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Fig. 1-4. Isolation of an agonist peptide for rat SLC-1.  A, purification procedure of 
an agonist peptide for rat SLC-1. The purification procedure comprised two parts of 
process, extraction from the rat brain tissues (step 1 to 3) and a combination of HPLCs 
(step 4 to 9). Agonist activity for rat SLC-1 was monitored with an assay of intracellular 
cAMP accumulation inhibition. B, mechanistic basis of the assay. Forskolin activates a 
membrane protein, adenylate cyclases (AC), which catalyzes the changes of ATP to cAMP. 
Ligand (L) as an agonist for rat SLC-1, which is able to suppress the AC activity through 
Gi protein activation results in inhibition of cAMP accumulation in CHO cells expressing 
rat SLC-1. 
  
A 
B 
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Fig. 1-5. HPLC profile of the final purification step using the Develosil ODS-UG-3 
column. Elution profile of the final purification step (upper panel) and agonist activities 
of the eluate (lower panel) are presented. The eluate was manually fractionated, and the 
agonist activity of the eluate was measured with an assay of intracellular cAMP 
accumulation inhibition in CHO-rat SLC-1 cells. The arrow marks the purified agonist 
peptide. 
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Fig. 1-6. Mass spectrometry of an agonist peptide for rat SLC-1. Mass spectrum of 
the agonist peptide was measured using a JEOL HX-110 Mass Spectrometer equipped 
with a cesium gun for the LSIMS mode. The arrow marks a peak of the protonated agonist 
peptide at the m/z value of 2387.2. 
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Fig. 1-7. Nucleotide sequence of human SLC-1 cDNA and its deduced amino acid 
sequence. A human SLC-1 cDNA was cloned from a cDNA library of the human 
embryonic brain. A deduced amino acid sequence of human SLC-1 was obtained from 
the nucleotide sequence with the longest open reading frame of the cDNA. Each sequence 
is placed with the nucleotide sequence above the amino acid sequence. Three Met 
residues as potential translation start site are boxed. Predicted transmembrane domains 
are underlined. The asterisk indicates a stop codon. 
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Fig. 1-8. Comparison of SLC-1 amino acid sequences among humans, rats, and mice. 
Deduced amino acid sequences of human and rat SLC-1 were obtained from the 
nucleotide sequences of the cloned human and rat SLC-1 cDNA, respectively, while 
amino acid sequence of mouse SLC-1 was obtained from the sequence data of 
NP_660114 registered in NCBI. Predicted transmembrane domains are underlined. The 
E/DRY motif is boxed in black. The NPXXY motif is boxed in blue. Three Met residues 
as potential translation start site are boxed in red.  
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Fig. 1-9. Inhibition of forskolin-induced cAMP accumulation by MCH in CHO cells 
expressing SLC-1. A, dose-dependent inhibition of cAMP accumulation in CHO-rat 
SLC-1 cells, in CHO-human SLC-1 (S) cells, in CHO-human SLC-1 (L) cells, and in 
CHO-mock cells. Various concentrations of MCH were added to all the cells, and an assay 
of cAMP accumulation inhibition was conducted in the presence of forskolin at 1 M. ■, 
CHO-rat SLC-1 cells; ▲, CHO-human SLC-1 (S) cells; △, CHO-human SLC-1 (L); ●, 
CHO-mock cells. B, selective activation of SLC-1 by MCH. Three natural ligands for the 
somatostatin receptor family, rat somatostatin-14, rat somatostatin-28, and rat cortistatin-
29 at 1 M, were added to the CHO-rat SLC-1 cells, and agonist activities of these ligands 
were measured with the assay of cAMP accumulation inhibition. Results shown are the 
means  S.E. (n = 3). 
  
B A 
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Chapter II: Discovery and Analysis of a Novel Brain-gut 
Peptide, Neuropeptide W as the Specific Ligand for the 
Orphan GPCRs, GPR7 and GPR8 
 
1. Introduction 
GPR7 and GPR8, for which the endogenous ligands have not been identified, are 
structurally related orphan GPCRs. The two genes encoding GPR7 and GPR8 were 
originally isolated from human genomic DNA by O’Dowd et al. (O’Dowd et al., 1995). 
Human GPR7 highly resembles human GPR8 with 64% amino acid identity. Among 
different families of GPCRs, GPR7 and GPR8 share high similarity to the opioid and 
somatostatin receptor families with known endogenous ligands. In the mammalian brain, 
GPR7 and GPR8 gene expression was detected by northern blot and in situ hybridization 
analyses (O’Dowd et al., 1995). Especially, in the rat brain, GPR7 mRNA was detected 
in regions of the cortex, hippocampus, and hypothalamus (Lee et al., 1999). Profiles of 
GPR7 and GPR8 expression mainly in the brain suggest that the endogenous ligands for 
the two receptors have several functions in the CNS. 
In Chapter II, the author attempted to purify the agonist peptide for GPR8 and report 
the purification, cloning, and characterization of neuropeptide W (NPW). The cDNA 
encoding the agonist peptide for GPR8 demonstrates the existence of neuropeptide W-23 
(NPW23) and neuropeptide W-30 (NPW30), which exhibit no meaningful similarity to 
any known peptides. The functional and binding characterization of NPW for GPR7 and 
GPR8 indicated that NPW is the endogenous ligand for both of these receptors. In order 
to ensure the existence of NPW at peptide levels, tissue distribution of NPW23 and 
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NPW30 was quantitatively examined using specific two-site enzyme-linked 
immunosorbent assays (ELISAs). In addition, the author describes the in vivo effects of 
NPW on feeding behavior and hormone release. 
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2. Materials and Methods 
2.1. Establishment of CHO cell lines expressing GPR7 and GPR8 
The coding region of human GPR7 was cloned from human genomic DNA and human 
brain cDNA, and that of human GPR8 was cloned from human brain cDNA by PCR 
(O’Dowd et al., 1995). An expression vector was constructed by ligation of the receptor 
gene to pAKKO-111H containing dhfr as a selection maker (Mori et al., 1999). CHO 
dhfr− cells were transfected with the expression vector. Stable cell lines of CHO 
expressing human GPR7 (CHO-GPR7) and CHO expressing human GPR8 (CHO-GPR8) 
were selected under conditions wherein the growth medium lacked nucleotides. 
 
2.2. Phylogenetic analysis of the GPCRs structurally similar to GPR7 and GPR8 
A phylogenetic analysis was conducted in the same way described in Chapter I. The 
description of SLC-1 was changed to melanin-concentrating hormone receptor 1 due to 
the successful deorphanization of SLC-1 as a MCH receptor, which was demonstrated in 
Chapter I. 
 
2.3. Gene expression profile of human GPR7 and GPR8 
Real-time PCR was used to measure copy numbers of GPR7, GPR8, and glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) cDNA molecules, which were synthesized from 
poly (A) RNA samples purified from various human tissues. Relative gene expression of 
GPR7 and GPR8 were defined as follows: the copy number of each GPR7 and GPR8 
divided by that of GAPDH as an internal control in each tissue sample. Human poly (A) 
RNA-derived cDNA samples of Multi Tissue cDNA Panels, and Marathon-Ready cDNA 
of each adipose and pituitary tissue were purchased from CLONTECH. Each solution of 
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the human cDNA samples was mixed with a TaqMan universal PCR master mix (PE 
Applied Biosystems) and each set of gene specific primers at final concentration of 0.2 
M and the gene specific probe at final concentration of 0.1 M in a 25 l of reaction 
mixture (Fujii et al., 2000). A calibration curve needed to convert a value of cycle 
threshold of the cDNA sample to a copy number of the target gene was created by adding 
known amounts of the GPR7, GPR8 or GAPDH DNA fragments instead of the test cDNA 
samples. The primers and probe synthesized for the real-time PCR were as follows: 
human GPR7, 5`-CATGAAGACCGTCACCAACCT-3` (forward primer), 5`-CCAGCG-
TGAAGAGCTCGTC-3` (reverse primer), and 5`-(FAM)-TTCATCCTCAACCTGGCC-
ATCGC-(TAMRA)-3` (probe). Each set of primers and probe to measure copy number 
of human GPR8 cDNA and human GAPDH cDNA was premixed with commercially 
available master mix solution (PE Applied Biosystems). The real-time PCR was carried 
out using an ABI PRISM 7700 Sequence Detector System (PE Applied Biosystems) 
under the following condition: 50°C for 2 min; 95°C for 10 min; 40 cycles of 95°C for 
15 sec, 60°C for 60 sec. 
 
2.4. Assay for inhibition of forskolin-induced intracellular accumulation of cAMP 
Inhibitory activities of test samples for cAMP accumulation was measured as described 
(Shimomura et al., 1999). CHO-GPR7 or CHO-GPR8 cells were plated on 24-well plates 
at 5  104 cells/well and were cultured for 2 days. The cells were washed three times with 
0.5 ml of assay buffer (Hanks’ buffered salt solution (pH 7.4), 0.2 mM 3-isobutyl-1-
methylxanthine (Wako Pure Chemical), 0.05% bovine serum albumin, and 20 mM 
HEPES) and were cultured in the assay buffer for 30 min. After washing the cells three 
times with 0.5 ml of the assay buffer, a test sample in 0.5 ml of the assay buffer 
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supplemented with 1 M forskolin (Wako Pure Chemical) was added to the cells, and the 
cells were incubated at 37°C for 30 min. cAMP synthesis in the cells was terminated by 
addition of 0.1 ml of 20% perchloric acid, and intracellular cAMP was extracted on ice 
for 1 h. The amount of extracted cAMP was measured using an enzyme-linked 
immunoassay kit (Amersham Biosciences). 
 
2.5. [35S]GTPS binding assay 
[35S]GTPS binding assay was performed essentially as described (Takekawa et al., 2002) 
with minor modifications. Membrane fractions of CHO-GPR8 cells suspended in 200 l 
of [35S]GTPS assay buffer (50 mM Tris-HCl (pH 7.4), 0.1% bovine serum albumin, 5 
mM MgCl2, 150 mM NaCl, and 1 M GDP) were mixed with a test sample, followed by 
addition of [35S]GTPS (PerkinElmer Life Sciences) at a final concentration of 0.5 nM. 
The mixture was incubated at 25°C for 60 min and was then filtered onto a Whatman 
GF/F glass filter. After washing three times with 1.5 ml of washing buffer (50 mM Tris-
HCl (pH 7.4), 0.1% bovine serum albumin, 5 mM MgCl2, and 1 mM EDTA), the glass 
filters were dried at 37°C for 60 min. The radioactivities retained on the glass filters were 
counted by a scintillation counter. 
 
2.6. Purification of NPW as an endogenous ligand for GPR8 from the porcine 
hypothalamus 
Approximately 500 g of fresh porcine hypothalamus was boiled for 10 min in pure water 
and was homogenized using a Polytron homogenizer in 2 liters of 1.0 M acetic acid. The 
homogenate was centrifuged, and then the supernatant was subjected to acetone 
precipitation at a final acetone concentration of 66%. After removal of the precipitates, 
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the supernatant was evaporated and was then extracted with diethyl ether. The resultant 
solution was applied to an YMCgel ODS-AM 120-S50 column (30.0 × 240 mm; YMC). 
The peptide fraction was eluted with 60% CH3CN in 0.1% trifluoroacetic acid, and the 
eluate was lyophilized. The agonist peptide for human GPR8 was purified from the 
lyophilized materials by successive HPLC using a TSKgel ODS-80TM column (21.5 × 
240 mm; 10–60% CH3CN gradient in 0.1% trifluoroacetic acid for 80 min at 5.0 ml/min; 
Tosoh), a TSKgel SP-5PW column (20 × 150 mm; 10–2000 mM HCOONH4 gradient in 
10% CH3CN for 40 min at 5.0 ml/min; Tosoh), a Develosil CN-UG-5 column (4.6 × 250 
mm; 21–26% CH3CN gradient in 0.1% trifluoroacetic acid for 20 min at 1.0 ml/min; 
Nomura Chemical), and a Wakosil-II 3C18HG column (2.0 × 150 mm; 22.5–32.5% 
CH3CN gradient in 0.1% trifluoroacetic acid for 40 min at 0.2 ml/min; Wako Bioproducts) 
combined with the [35S]GTPS binding assay. Finally, an active fraction with a single 
peak at both 220 and 280 nm was collected manually by HPLC using the Wakosil-II 
3C18HG column. The amino acid sequence of the purified peptide was analyzed with a 
protein sequencer, Procise 491cLC (Applied Biosystems, Inc.). 
 
2.7. Cloning of porcine, human, rat, and mouse NPW precursor protein cDNAs 
A BLAST search was performed using the amino acid sequence of the purified peptide as 
a query against the DDBJ/GenBankTM/EBI Data Bank. A human genomic DNA sequence 
(DDBJ/GenBankTM/EBI accession number AC0050606) contained a partial nucleotide 
sequence of which the translated amino acid sequence was similar to the purified peptide. 
On the basis of this DNA sequence, a cDNA encoding porcine NPW precursor protein 
was obtained from a porcine spinal cord cDNA library constructed with a Marathon 
cDNA amplification kit (CLONTECH) using 5`- and 3`-rapid amplification of cDNA 
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ends and PCR to clone full-length cDNA. Human NPW precursor protein cDNA, rat 
NPW precursor protein cDNA, and mouse NPW precursor protein cDNA were isolated 
from a human hypothalamus Marathon Ready cDNA library (CLONTECH), a rat brain 
Marathon Ready cDNA library (CLONTECH), and a mouse brain Marathon Ready 
cDNA library (CLONTECH), respectively, following the same strategies used to clone 
the porcine NPW precursor protein cDNA. The PCR primers for cloning the porcine, 
human, rat, and mouse full-length cDNAs were as follows: pig, 5`-
TTCCCGACACCCCTGCGCCCAGAC-3` (forward) and 5`-GGGCTGGCGAAGGCG-
GTTCCCTGC-3` (reverse); human, 5`-AGCGGTACTGAGGGGGCGGAACGA-3` 
(forward) and 5`-GGGTCTATGAGCGGCTCCTGGAAG-3’ (reverse); rat, 5'-GGGGC-
GGGGCCATTGAGAAGC-3' (forward) and 5`-TGACCAGACAACGAGACCTGA-3` 
(reverse); and mouse, 5`-AAAGGCTGTAGTCGCACCAAC-3` (forward) and 5`-
ACCAGAAACACGAGGCCTGAC-3` (reverse). The PCR conditions for cloning the 
porcine, human, rat, and mouse full-length cDNAs were as follows: pig, 96°C for 60 sec; 
4 cycles of 96°C for 30 sec, 72°C for 75 sec; 4 cycles of 96°C for 30 sec, 70°C for 75 sec; 
4 cycles of 96°C for 30 sec, 68°C for 75 sec; 5 cycles of 96°C for 30 sec, 64°C for 30 sec, 
72°C for 45 sec; 20 cycles of 96°C for 30 sec, 60°C for 30 sec, 72°C for 45 sec; 72°C for 
10 min; human, 96°C for 60 sec; 35 cycles of 96°C for 30 sec, 64°C for 30 sec, 72°C for 
120 sec; 72°C for 10 min; rat, 96°C for 60 sec; 35 cycles of 96°C for 30sec, 60°C for 30 
sec, 72°C for 60 sec; 72°C for 10 min; and mouse, 96°C for 120 sec; 40 cycles of 96°C 
for 30 sec, 64°C for 30 sec, 72°C for 120 sec; 72°C for 10 min. The porcine, human, rat, 
and mouse NPW precursor protein cDNA clones were sequenced on both strands using 
an ABI PRISM 377 DNA sequencer (PE Applied Biosystems). 
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2.8. Peptide synthesis of human, porcine, rat, and mouse NPW23 and NPW30 
Human, porcine, rat, and mouse NPW23 and NPW30 were chemically synthesized using 
an ABI 433A peptide synthesizer (Applied Biosystems, Inc.) following Fmoc (N-(9-
fluorenyl)methoxycarbonyl) strategy. After deblocking all the protecting groups by 
treatment with mixture of trifluoroacetic acid/thioanisole/m-cresol/triisopropylsilane/1, 
2-ethanedithiol (85:5:5:2.5:2.5), the peptides were purified by reverse phase HPLC. 
 
2.9. Comparison of the elution times of synthetic NPW with those of the 
[35S]GTPS binding activities of porcine hypothalamus fractions 
Extracts of the porcine hypothalamus were fractionated by HPLC using the TSKgel ODS-
80TM column (21.5 × 240 mm; 10–60% CH3CN gradient in 0.1% trifluoroacetic acid for 
80 min at 5.0 ml/min; Tosoh) as described above for the purification of NPW. Active 
fractions obtained by the HPLC were further fractionated by HPLC using a Develosil 
ODS-UG-5 column (4.6 × 250 mm; 25–40% CH3CN gradient in 0.1% trifluoroacetic acid 
for 30 min at 1.0 ml/min; Nomura Chemical), and the eluates were collected every 1 min. 
The agonist activity of each fraction for human GPR8 was measured by the [35S]GTPS 
binding assay. Synthetic porcine NPW23 and NPW30 were analyzed by HPLC using the 
Develosil ODS-UG-5 column (4.6 × 250 mm; 25–40% CH3CN gradient in 0.1% 
trifluoroacetic acid for 30 min at 1.0 ml/min). 
 
2.10. Expression and purification of human NPW in a transient expression system 
using COS-7 cells 
An expression vector was constructed by ligation of PCR-amplified human NPW 
precursor protein cDNA covering the DNA region from the 5` to 3` in-frame stop codons 
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to the mammalian expression vector pCR3.1 (Invitrogen). The PCR primers for cloning 
the human NPW precursor protein cDNA were 5`-AGCGGTACTGAGGGGGCGGA-
ACGA-3` (forward) and 5`-AACTAGTCGGCCACTCCTCCTGGGTCAG-3` (reverse). 
COS-7 cells were transfected with the expression vector and were cultured for 2 days. 
The conditioned medium was concentrated using a Sep-Pak Plus C18 cartridge (Waters). 
The agonist peptide for human GPR8 was purified from the concentrated medium by 
successive HPLC using a TSKgel CM-2SW column (4.6 × 250 mm; 10–2000 mM 
HCOONH4 gradient in 10% CH3CN for 60 min at 1.0 ml/min; Tosoh), a TSKgel ODS-
80TsQA column (4.6 × 250 mm; 25–45% CH3CN gradient in 0.1% trifluoroacetic acid 
for 60 min at 1.0 ml/min; Tosoh), and a SymmetryShield RP18 column (2.1 × 150 mm; 
15–35% CH3CN gradient in 0.1% trifluoroacetic acid for 60 min at 0.2 ml/min; Waters 
Associates) combined with the cAMP accumulation inhibition assay using CHO-GPR8 
cells. Finally, an active fraction with a single peak at 220 nm was collected manually by 
HPLC using the SymmetryShield RP18 column. The amino acid sequence of the purified 
peptide was analyzed with a Procise 491cLC protein sequencer (Applied Biosystems, 
Inc.). Electrospray ionization mass spectra of the purified peptide were recorded on an 
LCQ duo ion-trap mass spectrometer (ThermoFinnigan) equipped with a nanospray ion 
source (MDS Protana). 
 
2.11. Pertussis toxin treatment of CHO-GPR7 and CHO-GPR8 cells 
CHO-GPR7 and CHO-GPR8 cells were cultured in 24-well plates for 24 h and were then 
treated with or without pertussis toxin (List Biological Laboratories, Inc.) at a 
concentration of 100 ng/ml for 24 h. After washing these cells, the inhibitory effect of 
human NPW23 (1 nM) on cAMP accumulation induced by forskolin (1 M) was analyzed. 
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2.12. Receptor binding assay 
Human NPW23 was labeled by lactoperoxidase oxidation in the presence of Na125I 
(PerkinElmer Life Sciences), and the monoiodinated peptide labeled at Tyr10 was purified 
by reverse phase HPLC. Specific activity of the purified 125I-labeled human NPW23 was 
~9.5 × 1016 Bq/mol when a fresh batch of Na125I was used for labeling. Membrane 
preparation and receptor binding assay were performed essentially as described 
(Takekawa et al., 2002) with minor modifications. Membrane fractions of CHO-GPR7 
cells and CHO-GPR8 cells suspended in 200 l of receptor binding assay buffer (25 mM 
Tris-HCl (pH 7.4), 0.1% bovine serum albumin, 0.05% 3-((3-cholamidopropyl) 
dimethylammonio)-1-propanesulfonate (CHAPS), 5 mM EDTA, 0.5 mM 
phenylmethylsulfonyl fluoride, 0.1 g/ml pepstatin, 20 g /ml leupeptin, and 4 g /ml  
E-64) were mixed with 125I-labeled human NPW23. The mixture was incubated at 25°C 
for 75 min and was then filtered onto a Whatman GF/F glass filter. After washing three 
times with 1.5 ml of the binding buffer, the glass filters were dried at 37°C for 60 min. 
Nonspecific binding was determined by the binding assay in the presence of unlabeled 
human NPW23 at 1 M. The radioactivities retained on the glass filters were counted by 
a -counter. 
 
2.13. Generation of monoclonal antibodies to NPW23 and NPW30 
Three immunogens were prepared to obtain monoclonal antibodies recognizing the N-
terminal region of NPW23 and NPW30, the C-terminal region of NPW23, and the C-
terminal region of NPW30. Human [14Cys]NPW-[1–13] and human [1Cys]NPW-[11–23] 
were conjugated to porcine thyroglobulin, and rat [1Cys]NPW-[16–30] was conjugated to 
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keyhole limpet hemocyanin, by using sulfosuccinimidyl 4-(N-maleimidomethyl) 
cyclohexane-1 carboxylate (Pierce Chemical Co.). Female BALB/c mice (6–8 weeks old) 
were immunized with each immunogen, which was mixed with the Freund’s complete or 
incomplete adjuvant just before the immunization. The spleen cells isolated from the 
immunized mice 3 days after intravenous injection of the immunogens were fused with 
mouse myeloma cells, P3X63Ag8·653, as described previously (Suzuki et al., 1989). 
Three monoclonal antibodies, ANPW-N (IgG1, ) for the N-terminal region of NPW23 
and NPW30, ANPW23-C (IgG1, ) for the C-terminal region of NPW23, and ANPW30-
C (IgG2b, ) for the C-terminal region of NPW30, were screened, and IgG fractions of 
the three antibodies were purified from ascites fluids using an immobilized protein A 
column (SEIKAGAKU CORPORATION). 
 
2.14. Construction of two-site ELISAs to quantify immunoreactive NPW23 and 
NPW30 
The ANPW23-C and ANPW30-C were used as immobilized antibody for the two-site 
ELISAs of NPW23 and NPW30, respectively. The ANPW-N was conjugated to 
horseradish peroxidase (HRP) as described previously (Ichimori et al., 1987), and the 
HRP-labeled ANPW-N was used as the 2nd antibody to detect NPW23 and NPW30. The 
assay protocol of these two-site ELISAs was essentially the same as described by Ichimori 
et al. (Ichimori et al., 1987) with the following minor modifications. Immobilized 
antibody plates were prepared at 4°C by incubation with 20 μg/ml of the ANPW23-C for 
the NPW23 ELISA and with 20 μg/ml of the ANPW30-C for the NPW30 ELISA in 96-
well ELISA plates (50 mM sodium carbonate buffer (pH 9.6), 100 l/well) for an 
overnight followed by replacement of the antibody solution with 300 l/well of Block 
 47 
 
Ace (Snow Brand Milk Products Co., Ltd.). After the incubation with the Block Ace at 
least for an overnight, known amounts of the standard peptides, synthetic NPW23 and 
NPW30, and test samples in 100 μl of buffer C (20 mM phosphate buffer (pH 7.0), 1% 
bovine serum albumin, 0.4 M NaCl, and 2 mM EDTA) were added to each well of the 
antibody immobilized plates, and the plates were incubated at 4°C for 16 h. After washing 
with phosphate-buffered saline (PBS), the plates were treated with 100 μl/well of the 
HRP-labeled ANPW-N at a 1000-fold dilution in buffer C at 4°C for an additional 16 h. 
After washing with PBS, bound enzyme activity was measured using a TMB microwell 
peroxidase system (Kirkegaard and Perry Laboratories). 
 
2.15. Preparation of peptide fractions from animal organs for the measurement of 
immunoreactive NPW23 and NPW30 
Fresh animal organs were used to prepare samples for the ELISAs of NPW23 and NPW30. 
Each porcine organ (the whole brain, spinal cord, hypothalamus, pituitary, adrenal gland, 
esophagus, stomach, duodenum, small intestine, atrium, spleen, pancreas, kidney, ovary, 
thymus, and lung) with its total weight around 500 g was boiled for 10 min in 2 liters of 
pure water and was subsequently homogenized by a Polytron homogenizer in the same 
volume of 1.0 M acetic acid. The homogenate was centrifuged, and subsequently the 
supernatant was subjected to acetone precipitation at a final acetone concentration of 66%. 
After removal of the precipitates, the supernatant was evaporated and was extracted with 
diethyl ether. The resultant solution was applied to an YMCgel ODS-AM 120-S50 
column (30.0 × 240 mm; YMC). Peptide fraction was eluted with 60% CH3CN in 0.1% 
trifluoroacetic acid, and the eluate was lyophilized. The lyophilized material dissolved in 
1.0 M acetic acid was purified by the following HPLC using a TSKgel ODS-80TM 
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column (21.5 × 240 mm; 10–60% CH3CN gradient in 0.1% trifluoroacetic acid for 80 
min at 5.0 ml/min; Tosoh). Each fraction obtained from the second HPLC was lyophilized, 
and the lyophilized materials in tubes were dissolved in DMSO as assay samples for the 
ELISAs. Rodent organs were dissected from male Wistar rats (6–8 weeks old) and male 
C57BL/6 mice (6–8 weeks old): rats, the whole brain, spinal cord, pituitary, stomach, 
duodenum, colon, heart, spleen, pancreas, liver, kidney, testis, and lung; and mice, the 
whole brain, pituitary, and stomach. Each rodent organ described above was boiled for 10 
min in pure water with its weight equivalent to at least 4 times weight of the organ and 
was subsequently homogenized by a Polytron homogenizer in the same volume of 1.0 M 
acetic acid. Supernatant of the initial extraction was obtained by centrifugation, and the 
residual tissue as a pellet was re-homogenized by the Polytron homogenizer in the same 
volume of 1.0 M acetic acid. Supernatant of the second extraction was obtained by the 
centrifugation and was mixed with that of the initial extraction followed by a semi-
purification using an octadecyl-bonded silica cartridge, Sep-Pak C18 Classic Cartridge 
(Waters). The mixture of the extract was absorbed onto the Sep-Pak C18 Classic Cartridge 
followed by washing with 1.0 M acetic acid, and peptide fraction was eluted with 60% 
CH3CN in 0.1% trifluoroacetic acid. The eluates were lyophilized, and the lyophilized 
materials were dissolved in the buffer C as assay samples for the ELISAs. Quantities of 
immunoreactive NPW23 and NPW30 in the assay samples were calculated as the average 
of duplicate assays. 
 
2.16. Feeding experiments 
Male Wistar rats (8–9 weeks old) were maintained under controlled temperature (25°C) 
and lighting (light on from 7:30 to 19:30). Food (standard chow pellets) and water were 
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available ad libitum. A stainless-steel guide cannula (AG-8, EICOM, Kyoto, Japan) was 
inserted into the lateral ventricle under sodium pentobarbital anesthesia. After the rats had 
been housed for 1 week in individual cages, 10 l of PBS with or without human NPW23 
was injected at a flow rate of 5 l/min into the lateral ventricle through a microinjection 
cannula that was inserted into the guide cannula. All injections started at 15:00, and food 
intake was measured at 30, 60, and 120 min. 
 
2.17. Hormone release experiments 
Male Wistar rats (8–9 weeks old) were maintained under controlled temperature (25°C) 
and lighting (light on from 7:30 to 19:30). Food (standard chow pellets) and water were 
available ad libitum. A stainless-steel guide cannula (AG-12, EICOM, Kyoto, Japan) was 
inserted into the third ventricle under sodium pentobarbital anesthesia. The cannula-
implanted rats were housed in individual cages and kept for 1 week. One day before the 
experiments, the cannula-implanted rats were fitted with a catheter in the right jugular 
vein. The following day, 10 l of PBS with or without human NPW23 was injected at a 
flow rate of 5 l/min into the third ventricle through a microinjection cannula that was 
inserted into the guide cannula. An intracerebroventricular injection was given between 
13:00 and 15:00. After the intracerebroventricular injection of the peptide, blood samples 
were collected from the catheter at 5, 10, 20, 30, and 60 min. The concentration of 
prolactin in the plasma samples was then determined using a radioimmunoassay kit 
(Amersham Biosciences). 
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3. Results 
3.1. Structural and gene expression features of GPR7 and GPR8 
GPR7 and GPR8 are structurally related orphan GPCRs with an amino acid identity of 
64% (O’Dowd et al., 1995). The two orphan GPCRs showed sequence similarity to other 
human GPCRs, human orthologue of the rat SLC-1, five subtypes of the somatostatin 
receptor, three subtypes of the opioid receptor, and one opioid-like receptor. A 
phylogenetic tree of the twelve above mentioned GPCRs and the rat SLC-1 was 
constructed by the neighbor-joining method. The two orphan GPCRs, GPR7 and GPR8, 
showed the highest homology to each other (Fig. 2-1). The closest group of GPCRs to the 
two orphan GPCRs was the subtypes of the opioid receptor with the opioid-like receptor.  
Gene expression patterns of GPR7 and GPR8 in human tissues were examined by real-
time PCR. Both GPR7 and GPR8 are moderately expressed in the brain, testis, and 
pituitary (Fig. 2-2). Other tissues in which either GPR7 or GPR8 are expressed to the 
same degree as that in the brain are the liver, small intestine, and spleen. 
 
3.2. Purification and cDNA cloning of the agonist peptide for human GPR8 
The author purified the agonist peptide for human GPR8 from the porcine hypothalamus 
using CHO-GPR8 cells, using the so-called “reverse pharmacology” technique (Libert et 
al., 1991; Kotarsky and Nilsson, 2004). While assessing intracellular signal changes in 
CHO-GPR8 cells induced by the test samples, including various tissue extracts and 
known bioactive substances, reverse phase HPLC fractions of the porcine hypothalamus 
extracts showed an inhibitory effect on cAMP accumulation induced by forskolin. 
Treatment of the reverse phase HPLC fractions with proteinases diminished the agonist 
activity (data not shown), suggesting that a peptide ligand for human GPR8 was present 
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in the porcine hypothalamus extracts. Because the same reverse phase HPLC fractions 
also stimulated [35S]GTPS binding to membranes of CHO-GPR8 cells, the porcine 
hypothalamus extracts were subjected to purification by successive chromatography to 
isolate an agonist peptide for human GPR8 (Fig. 2-3A). Its activity was assessed using 
the [35S]GTPS binding assay (Fig. 2-3B). The process yielded 3 pmol of the purified 
agonist peptide for human GPR8 from 500 g of the porcine hypothalamus (Fig. 2-4A and 
B). The N-terminal amino acid sequence of the purified peptide was determined to be 
WYKHTASPRYHTVGRAAXLL (X, not identified) using a protein sequencer. 
The author then attempted to isolate the cDNA encoding this peptide to reveal its whole 
amino acid sequence. A cDNA was cloned from a porcine spinal cord cDNA library by 
PCR using DNA sequence information obtained by both 5- and 3-rapid amplification of 
cDNA ends. Although two ATG codons present in the 5-end region of the isolated cDNA 
preceded an in-frame stop codon (DDBJ/GenBankTM/EBI accession number AB084277), 
the 2nd ATG codon conforms more to the rules of Kozak (Kozak, 1996). The open reading 
frame starting at the 1st ATG codon encodes a porcine polypeptide of 159 amino acid 
residues (Fig. 2-5). The PSORT II algorithm based on the method of von Heijne (von 
Heijne, 1986) demonstrated that a signal peptide cleavage site of this polypeptide exists 
between Ala39 and Trp40 (von Heijne, 1986; Nakai and Horton, 1999). Therefore, it is 
predicted that two mature peptides of 23 and 30 amino acid residues will be generated 
from the precursor protein by signal peptide cleavage and proteolytic processing at two 
pairs of basic amino acid residues, Arg63-Arg64 and Arg70-Arg71, respectively (Douglass 
et al., 1984). The mature peptide sequence of the 23-amino acid residue peptide starts at 
Trp40 and ends at Leu62, whereas that of the 30-amino acid residue peptide starts at Trp40 
and ends at Trp69. The amino acid sequence of the 23-amino acid residue peptide is 
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identical to that of the N-terminal 23 amino acid residues in the 30-amino acid residue 
peptide. Since both the first and last amino acids of the 30-amino acid residue peptide are 
tryptophan, the 30-amino acid residue peptide was designated as neuropeptide W-30 
(NPW30), and then the 23-amino acid residue peptide was designated as neuropeptide W-
23 (NPW23). 
 
3.3. Activation of human GPR8 by NPW23 and NPW30 in the porcine 
hypothalamus 
To clarify the molecular species showing agonist activities for human GPR8, the author 
measured the [35S]GTPS binding activities of the porcine hypothalamus peptide 
fractions for human GPR8 and compared the elution times of the fractions with 
[35S]GTPS binding activities with those of synthetic peptides of porcine NPW23 and 
NPW30 under the same HPLC conditions. The synthetic porcine NPW23 and NPW30 
were eluted at 24.5 min and at 26.5 min, respectively (Fig. 2-6A). The [35S]GTPS 
binding activities of the porcine hypothalamus peptide fractions for human GPR8 were 
recovered mainly in fractions 25 (24–25 min) and 27 (26–27 min) with almost the same 
activity (Fig. 2-6B), indicating that fractions 25 and 27 contained porcine NPW23 and 
NPW30, respectively. These results suggest that porcine NPW23 and NPW30 present in 
the porcine hypothalamus activate human GPR8. 
 
3.4. Structures of NPW precursor protein and mature NPW peptide 
The author isolated human NPW precursor protein cDNA (DDBJ/GenBankTM/EBI 
accession number AB084276) lacking an AUG start codon from a human hypothalamus 
cDNA library and examined whether human NPW with agonist activity for human GPR8 
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is generated from this cDNA. As shown in Fig. 2-7, an open reading frame of the cDNA 
represents the amino acid sequences of NPW23 and NPW30, which are flanked by a 
putative signal peptide cleavage site and a pair of basic amino acid residues and which 
show amino acid sequence similarity to porcine NPW23 and NPW30, respectively. 
Although an AUG start codon is not present near the 5-end of the cDNA, several potential 
non-AUG start codons lie within the region (Peabody, 1989; Mehdi et al., 1990). To 
ensure that the agonist peptide for human GPR8 is synthesized from this human cDNA, 
the author analyzed peptides secreted from COS-7 cells that were transfected with an 
expression vector containing this human cDNA. The supernatant of COS-7 cells 
transfected with this vector showed an inhibitory effect on forskolin-induced cAMP 
accumulation specifically in CHO-GPR8 cells. From 900 ml of the supernatant, 150 pmol 
of the agonist peptide for human GPR8 was purified to homogeneity (Fig. 2-8A and B). 
The structure of the purified peptide was WYKHVASPRYHTVGRAAGLLM (NPW21), 
lacking 2 amino acid residues at the C terminus compared with the predicted human 
NPW23 sequence. In this expression system, translation of the precursor protein and 
signal peptide cleavage proceeded as expected, but the proteolytic processing at a pair of 
basic amino acid residues failed to proceed accurately. These results indicate that the 
agonist peptide for human GPR8 is generated through intracellular processing of the 
precursor protein initiated from a non-AUG start codon in the transcript of the human 
NPW precursor protein cDNA. 
The author subsequently isolated cDNA clones encoding rat NPW precursor protein 
and mouse NPW precursor protein. A cDNA encoding rat NPW precursor protein 
(DDBJ/EMBL/Gen-BankTM accession number AB084278) demonstrated the existence of 
a precursor protein of 185 amino acid residues, which is translated from the longest open 
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reading frame in the cDNA nucleotide sequence (Fig. 2-9). The amino acid sequence of 
the rat NPW precursor protein includes a signal peptide cleavage site between Ala41 and 
Trp42, which was predicted by the PSORT II algorithm (Nakai and Horton, 1999) and two 
pairs of basic amino acid residues, Arg65-Arg66 and Arg72-Arg73. Two peptides of 23 and 
30 amino acid residues are predicted to be generated from the precursor protein as mature 
peptides via the signal peptide cleavage between Ala41 and Trp42 followed by proteolytic 
processing at the amino terminal ends of the Arg65-Arg66 and the Arg72-Arg73, respectively. 
The mature peptide sequences of rat NPW23 and rat NPW30 are suggested to be 
WYKHVASPRYHTVGRASGLLMGL and WYKHVASPRYHTVGRASGLLMGLRR-
SPYLW, respectively. As for the human NPW precursor nucleotide sequence, a cDNA of 
the mouse NPW precursor protein lacking an AUG start codon presented two peptide 
sequences of 23 and 30 amino acid residues, which are flanked by a putative signal 
peptide cleavage site and by two pairs of Arg-Arg basic amino acid residues (Fig. 2-10). 
The amino acid sequences of the 23- and 30-amino acid residue peptides in the mouse 
NPW precursor protein are quite similar to those of the human, porcine, and rat NPW23 
and NPW30 (Fig. 2-11). 
The author compared the amino acid sequences of NPW precursor protein and mature 
NPW peptide from the humans, pigs, rats, and mice. A deduced amino acid sequence of 
each porcine and rat NPW precursor protein was defined unambiguously as the translated 
protein from the open reading frame of the cloned cDNA with normal AUG start codons. 
Since each cDNA encoding human and mouse NPW precursor protein lacked the AUG 
start codon, the author assumed that a potential non-AUG start codon was either ACG, 
CUG, or GUG, which existed at 123-base to 96-base upstream of the tryptophan codon 
for the N-terminal amino acid of the mature NPW peptide sequences due to the fact that 
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the AUG start codon of the porcine and rat NPW precursor protein nucleotides was placed 
in the same region. As a result, the human NPW precursor protein, 165 amino acids, with 
translation initiated from the CUG codon at the nucleotide position 187–189 and the 
mouse NPW precursor protein, 176 amino acids, with translation initiated from the CUG 
codon at the nucleotide position 121–123 were aligned with the porcine and rat NPW 
precursor proteins using CLUSTAL W multiple sequence alignment (Fig. 2-12). The 
alignment pointed out the conserved amino acid sequences and motifs: a putative signal 
peptide sequence with hydrophobic amino acids, leucine or proline, mature NPW peptide 
sequences of NPW23 and NPW30, and two pairs of Arg-Arg basic amino acid residues. 
Especially, the amino acid sequences of the mature NPW peptide, NPW23 and NPW30 
showed quite higher sequence similarity among the four species, 91.3 and 90.0%, 
respectively. Both the N- and C-terminal amino acids of NPW are conserved such that the 
amino acid sequence of NPW23 starts at tryptophan and ends at leucine, and that of 
NPW30 starts at tryptophan and ends at tryptophan. 
Thus, the author identified novel bioactive peptides, NPW23 and NPW30 that are 
encoded by the NPW precursor gene. The database search was conducted with the BLAST 
and the FASTA programs using the amino acid sequences of NPW23 and NPW30 as 
queries against as diverse as protein and DNA sequence databases available. The amino 
acid sequences of NPW23 and NPW30 did not show significant similarity to any known 
proteins registered in those databases. The database search results demonstrated that 
NPW was first discovered by this study aiming at the deorphanization of GPR8. 
 
3.5. Functional activity and binding affinity of NPW for GPR7 and GPR8 
The author examined the functional activity and binding affinity of synthetic NPW for 
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human GPR7 and GPR8 because human GPR8 shows higher similarity to human GPR7 
than to other numerous GPCRs. Human NPW23 dose-dependently inhibited cAMP 
accumulation induced by forskolin in CHO-GPR7 and CHO-GPR8 cells, with IC50 values 
of 0.025 and 0.178 nM, respectively (Fig. 2-13A and B; and Table 2-1). Human NPW30 
also showed an inhibitory effect on forskolin-induced cAMP accumulation in CHO-GPR7 
and CHO-GPR8 cells, with IC50 values of 0.133 and 1.244 nM, respectively (Fig. 2-13 A 
and B; and Table 2-1). In CHO-GPR7 and CHO-GPR8 cells, no elevation of intracellular 
calcium induced by NPW23 and NPW30 was observed by measurement of [Ca2+]i 
response using a calcium fluorescent dye indicator, Fluo 3-AM (data not shown), and the 
inhibitory effect of NPW on forskolin-induced cAMP accumulation was abolished by 
preincubation with pertussis toxin (Fig. 2-13C and D), indicating that human GPR7 and 
GPR8 both are coupled with the Gi protein. Saturation binding analysis using 125I-labeled 
human NPW23 showed that membrane fractions of CHO-GPR7 and CHO-GPR8 cells 
displayed high affinity, saturable, and specific binding (human GPR7, Kd = 31.8  3.0 
pM and Bmax = 2.02  0.10 pmol/mg; human GPR8: Kd = 20.7  0.6 pM and Bmax = 
4.37  0.04 pmol/mg) (Fig. 2-13E and F). 125I-labeled human NPW23 bound both human 
GPR7 and GPR8 with nearly the same affinity. Competition binding analysis 
demonstrated high affinity binding of NPW23 and NPW30 to human GPR7 and GPR8 
(Table 2-1). NPW binds to and activates these receptors with high affinity and potency. 
These results indicate that NPW is the endogenous ligand for both GPR7 and GPR8. 
 
3.6. Tissue distribution of immunoreactive NPW23 and NPW30 
The author created two-site ELISAs to assess the tissue distribution of the mature NPW 
peptides, NPW23 and NPW30. The two-site ELISAs were essentially constructed with 
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three monoclonal antibodies, the ANPW-N, the ANPW23-C, and the ANPW30-C, which 
recognize the N-terminal sequence of both NPW23 and NPW30, the C-terminal sequence 
of NPW23, and the C-terminal sequence of NPW30, respectively. The ANPW23-C and 
ANPW30-C were used as immobilized antibodies to trap NPW23 and NPW30, 
respectively, by binding to individual C-terminal regions, and the ANPW-N labeled with 
HRP was used as the 2nd antibody to capture the free N-terminal regions of the NPW23 
and NPW30, which were already trapped by the immobilized antibodies in 96-well 
ELISA plates. The two ELISAs, NPW23 ELISA and NPW30 ELISA enabled the specific 
measurement of human, porcine, rat, and mouse NPW23 and NPW30 with a minimum 
detectable quantity of 0.3 fmol/well (Fig. 2-14). 
The author observed a preferential expression of NPW23 and NPW30 peptides in the 
brain, pituitary, and stomach in a variety of animal tissues. Porcine peptide fractions 
prepared from sixteen different organs (the brain, spinal cord, hypothalamus, pituitary, 
adrenal gland, esophagus, stomach, duodenum, small intestine, atrium, spleen, pancreas, 
kidney, ovary, thymus, and lung) were used for the measurement of NPW23 and NPW30 
by the two-site ELISAs. Significant levels of immunoreactive NPW23 (ir-NPW23) and 
immunoreactive NPW30 (ir-NPW30) were detected in the brain, spinal cord, 
hypothalamus, pituitary, adrenal gland, stomach, and duodenum (Table 2-2). Rat peptide 
fractions prepared from thirteen different organs (the brain, spinal cord, pituitary, stomach, 
duodenum, colon, heart, spleen, pancreas, liver, kidney, testis, and lung) were applied to 
the two-site ELISAs, and significant levels of ir-NPW23 and ir-NPW30 were detected in 
the brain, spinal cord, pituitary, and stomach. Mouse peptide fractions were prepared from 
a limited number of organs (the brain, pituitary, and stomach) where both porcine and rat 
NPW peptides were detected as mentioned above. Significant amounts of ir-NPW23 and 
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ir-NPW30 were detected in all the mouse peptide fractions. The two-site ELISAs for the 
extracts of porcine, rat, and mouse organs demonstrated that NPW23 and NPW30 are 
preferentially localized in the brain, pituitary, and stomach. 
 
3.7. In vivo effects of NPW on feeding behavior and hormone release 
The author investigated the central effects of NPW on feeding behavior and hormone 
release because rat GPR7 is expressed at relatively high levels in the brain (Lee et al., 
1999). First, human NPW23 was intracerebroventricularly administered to rats, and food 
intake was monitored (Fig. 2-15A). Injection of 10 nmol of NPW23 significantly 
increased food intake, and the magnitude of food consumption during a 2-h period was 
about 3-fold relative to vehicle controls. Second, human NPW23 was 
intracerebroventricularly administered to rats, and hormone concentrations in the blood 
were measured (Fig. 2-15B). Injection of 3 nmol of NPW23 significantly stimulated the 
release of prolactin, but not the release of other pituitary hormones such as growth 
hormone, adrenocorticotropic hormone, follicle-stimulating hormone, luteinizing 
hormone, and thyroid-stimulating hormone. The prolactin concentration increased to 
maximum levels 20 min after injection and decreased to control levels after 60 min. 
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4.  Discussion 
The author purified a novel bioactive peptide, NPW, as the agonist for GPR8 using CHO 
cells expressing human GPR8 from the porcine hypothalamus. The discovery of NPW 
resulted from the attempt of the deorphanization of GPR8. The purified peptide is 
encoded by the porcine NPW precursor gene, and the precursor protein sequence predicts 
the existence of two mature peptides composed of 23 and 30 amino acid residues. The 
author demonstrated the existence of the 23- and 30-amino acid residue NPW peptides as 
mature peptides in the porcine hypothalamus by HPLC analysis combined with the 
[35S]GTPS binding assay (Fig. 2-6A and B). The porcine hypothalamus contained nearly 
equal amounts of NPW23 and NPW30 because both fractions 25 and 27 showed nearly 
the same agonist activity, indicating that NPW23 and NPW30 would exhibit their own 
biological activities in the mammalian body. 
Uniqueness of the human NPW precursor protein cDNA sequence postulated that 
translation of human NPW precursor protein, unlike that of pigs and rats, is not initiated 
from a typical AUG start codon. The author demonstrated that NPW21 with agonist 
activity for human GPR8 was synthesized from the human NPW precursor protein cDNA 
lacking an AUG start codon in a transient expression system using COS-7 cells. In this 
expression system, translation of the human NPW precursor polypeptide was initiated 
from a non-AUG start codon, and the signal peptide cleavage subsequently occurred at 
an expected site, but the proteolytic processing of the polypeptide failed to create the 
expected C terminus of mature NPW, probably due to an incomplete set of processing 
enzymes in the COS-7 cells (Galanopoulou et al., 1993) or susceptibility to proteolysis of 
the C terminus of mature NPW in the culture medium. Natural non-AUG start codons are 
very rare in eukaryotes, but have been detected in c-Myc, fibroblast growth factor-2, 
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vascular epidermal growth factor, MHC, and TRPV6 (Hann et al., 1988; Prats et al., 1989; 
Meiron et al., 2001; Starck et al., 2012; Fecher-Trost et al., 2013). In almost all cases, 
alternate initiation takes place at upstream non-AUG codons in addition to the first in-
frame AUG codons. Non-AUG triplets functioning as start codons have been 
experimentally determined to be ACG, CUG, and GUG (Peabody, 1989; Mehdi et al., 
1990). If initiation of the human NPW precursor polypeptide translation takes place at a 
position that corresponds to the AUG start site in the porcine or rat NPW precursor 
mRNAs, a CUG triplet (nucleotides 187–189) is one of the candidates for the non-AUG 
start codon in human NPW precursor mRNA (Fig. 2-7). Although further research is 
required to determine the translation start site and the usage of the non-AUG start codon 
in the human NPW precursor mRNA, it is proposed that human NPW is encoded by the 
nucleotide sequence of the human NPW precursor protein cDNA with a unique translation 
from a non-AUG start codon and that the mature forms of human NPW are NPW23 
(WYKHVASPRYHTVGRAAGLLMGL) and NPW30 (WYKHVASPRYHTVGRAAG-
LLMGLRRSPYLW).  
The mouse NPW precursor protein cDNA sequence lacking an AUG-start codon 
suggested that translation of its precursor protein is initiated from a non-AUG codon as 
experimentally elucidated for the translation of human NPW precursor protein. A CUG 
triplet (nucleotides 121–123) was supposed to be a potential non-AUG start codon if the 
translation initiation takes place at the same position as that in porcine or rat NPW 
precursor mRNAs (Fig. 2-10). The author has not attempted to ensure whether agonist 
peptides for GPR8 are synthesized from mouse Npw precursor mRNA using an 
experimental system with COS-7 cells that are transfected with the mouse NPW precursor 
protein cDNA. However, mature peptide forms of mouse NPW precursor protein, NPW23 
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and NPW30, have been detected in the mouse brain, pituitary, and stomach by 
quantitative measurement using the NPW23- and NPW30-specific two-site ELISAs 
(Table 2-2). Thus, it is proposed that mouse NPW is encoded by the nucleotide sequence 
of the mouse NPW precursor protein cDNA with a unique translation from a non-AUG 
start codon and that the mature forms of mouse NPW are NPW23 (WYKHVASPRYHTV-
GRASGLLMGL) and NPW30 (WYKHVASPRYHTVGRASGLLMGLRRSPYQW). 
The amino acid sequence features of human, porcine, rat, and mouse NPW precursor 
proteins indicate a possible biosynthetic pathway mechanism for the mature NPW 
peptides. NPW23 and NPW30 are generated from their precursor proteins by a post-
translational modification, including the translocation of the NPW precursor proteins 
presenting signal peptide sequences across the ER membrane and processing at the two 
sites of the Arg-Arg basic amino acid residues in the regulated secretory vesicles. After 
initiation of protein translation, a signal recognition particle that binds to the signal 
peptide sequence in the NPW precursor protein conveys the translation complex with the 
ribosomes on the ER membrane in the cytosol (Nagai et al., 2003; Akopian et al., 2013). 
The polypeptide chain elongating inside the translocon, a transmembrane protein 
complex with channel activity, is then released into the ER lumen after completion of 
signal peptide cleavage and termination of the translation. The resulting proprotein of 
NPW undergoes proteolytic processing at the N-terminal Arg-Arg residue site by 
endoprotease in the regulated secretory vesicles (Seidah and Prat, 2012). As a 
consequence of the signal peptide cleavage and the processing at the two pairs of the basic 
amino acid residues, the NPW precursor proteins are converted to the mature peptide 
forms, NPW23 and NPW30. 
Human NPW23 and NPW30 inhibited forskolin-induced cAMP accumulation in both 
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CHO-GPR7 and CHO-GPR8 cells, with subnanomolar or nanomolar IC50 values. In 
competition binding studies, human NPW23 and NPW30 showed high binding affinity 
for both GPR7 and GPR8, with subnanomolar IC50 values. The high potency and affinity 
of NPW23 and NPW30 for both GPR7 and GPR8 indicate that NPW23 and NPW30 are 
the endogenous ligands for both GPR7 and GPR8. A slight difference between NPW23 
and NPW30 was observed that NPW23 showed a tendency to activate both GPR7 and 
GPR8 more efficiently compared with NPW30. In the cAMP accumulation inhibition 
assay, the IC50 values of NPW23 for GPR7 and GPR8 were 5.3- and 7.0-fold lower than 
those of NPW30 for the two receptors, respectively (Table 2-1). In contrast, NPW30 
showed a tendency to bind to both GPR7 and GPR8 with high affinity compared with 
NPW23. In the competition binding assay, the IC50 values of NPW30 for GPR7 and GPR8 
were 3.8- and 10.0-fold lower than those of NPW23 for the two receptors, respectively 
(Table 2-1). The C-terminal 7 amino acid residues in human NPW30 should result in 
relatively low potency and high affinity of NPW30 for its receptors compared with 
NPW23. Structure-activity relationship studies of NPW are required to reveal the roles of 
the C-terminal 7 amino acid residues in the activation of and binding to its receptors. 
Two-site ELISAs were developed to assess the tissue distribution of NPW23 and 
NPW30, which underlies predictions of where NPW exerts its biological functions in vivo. 
The two-site ELISAs constructed by using three different monoclonal antibodies enabled 
the specific and sensitive quantification of NPW23 and NPW30 in the tissue extracts from 
pigs, rats, and mice. The author measured the amounts of ir-NPW23 and ir-NPW30 in a 
variety of organs from pigs, rats, and mice and demonstrated that NPW23 and NPW30 
are commonly localized in the brain, pituitary, and stomach of these three animals (Table 
2-2). Although significant amounts of ir-NPW23 and ir-NPW30 were detected in the 
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spinal cord of pigs and rats, the existence of NPW in the mouse spinal cord could not be 
ensured due to technical difficulties in the resection of a sufficient amount of the mouse 
spinal cord tissues for the two-site ELISAs. Clarification of whether the mouse spinal 
cord produces NPW will help to obtain definitive information on the tissue distribution 
pattern of NPW. In spite of the detection of immunoreactive NPW (ir-NPW) in the porcine 
duodenum, it is believed that the duodenum cannot be an organ that produces NPW. The 
significant amounts of NPW in the extract from the porcine duodenum in those assays 
might result from contamination of the lower part of NPW-producing porcine stomach 
tissues adjacent to the duodenum tissues when the duodenum tissues used as assay 
samples were cut at a public slaughterhouse. Besides that, the author obviously showed 
that no ir-NPW was detected in the tissues of rat duodenum, which were carefully 
removed from the adjacent organs such as the stomach and small intestine in our animal 
research facilities. These results indicate that NPW23 and NPW30 are categorized into 
brain-gut peptides. 
The data on the tissue distribution of NPW peptides or the gene expression profile of 
its receptors, GPR7 and GPR8, allowed us to unravel unknown biological functions of 
NPW. The existence of NPW peptides as well as GPR7 and GPR8 gene expression in the 
brain naturally predicted that NPW acts as a neurotransmitter in the CNS. The localization 
of NPW peptides in the stomach and pituitary that have a function of endocrine activity 
raised the possibility that the NPW stored in these organs is being released into the 
bloodstream and subsequently reaches to the target tissues where the NPW activates 
GPR7 and GPR8. Further histological studies using techniques of immunohistochemistry 
and in situ hybridization for NPW and its receptors will enable us to obtain information 
on the cellular distribution of NPW and its receptors, which might narrow down focus 
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when attempting to elucidate the biological functions of NPW.  
An exploratory study on the in vivo effects of NPW was conducted to determine the 
physiological and pathophysiological roles of NPW. The author demonstrated that NPW 
was functioning as a neurotransmitter, modulating feeding behavior and neuroendocrine 
release. In rats, intracerebroventricular administration of NPW23 resulted in an acute 
increase in food intake. The orexigenic effect could be accounted for by activation of 
GPR7-expressing neurons localized in the hypothalamic areas, which are considered to 
regulate feeding behavior and energy homeostasis (Spiegelman and Flier, 2001). 
Stimulation of prolactin release was observed upon the intracerebroventricular 
administration of NPW23. Although GPR7 is expressed in the pituitary gland, where 
prolactin is secreted in response to physiological stimuli (Wynick et al., 1998; Yang et al., 
2000), further studies will be required to determine whether NPW activates the pituitary 
cells directly or indirectly by other mechanisms. To define the physiological importance 
of NPW in complex pathways of feeding behavior and prolactin release, development of 
selective antagonists for the receptors of NPW and genetically engineered mice with a 
deletion of NPW or its receptor genes will be useful. In addition to the effects of NPW on 
feeding behavior and prolactin release, the broad expression patterns of GPR7 and GPR8 
in the mammalian brain raise the possibility that NPW influences many physiological 
processes in the CNS. 
Some GPCRs have more than one endogenous ligand, which activates and binds to 
receptors of the same family (Inoue et al., 1989). These endogenous ligands share 
structural similarity or common motifs in their peptide sequences and are usually encoded 
by different genes. The structurally related GPCRs, GPR7 and GPR8, are functional 
receptors for NPW23 and NPW30, which are encoded by the NPW precursor gene. In the 
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search for an endogenous ligand for GPR7 or GPR8, it was not possible to identify other 
endogenous ligands with structures different from that of NPW. However, these results 
do not exclude the possibility that other endogenous ligands may exist for GPR7 or GPR8. 
Since the discovery and molecular characterization of NPW reported in 2002, much 
attention has been paid on the understanding of the biological functions of NPW and its 
receptors. The followings are summary of the advancements in the elucidation of the 
NPW’s biological functions. Regulation of feeding behavior and energy homeostasis by 
NPW was investigated with a high priority due to the initial finding that NPW acutely 
increased food intake in the light phase (Shimomura et al., 2002; Levine et al., 2005). 
Mondal et al. reported that the intracerebroventricular administration of NPW acutely 
decreased food intake in the dark phase, and the continuous intracerebroventricular 
infusion of NPW suppressed food intake and body weight gain in rats (Mondal et al., 
2003). In the single intracerebroventricular administration of NPW experiment, rise in 
body temperature and heat production were also observed. An experiment using 
genetically modified mice with null mutation of GPR7 confirmed NPW function as a 
regulator of feeding behavior and metabolism. Rodents present an orthologue of human 
GPR7, but not an orthologue of human GPR8. Ishii et al. demonstrated that male Gpr7-/- 
mice developed adult-onset obesity along with hyperphagia (Ishii et al., 2003). Studies 
on the molecular mechanism involved in NPW anorectic activity in the brain (Date et al., 
2010) and cellular level distribution of NPW-positive neurons (Dun et al., 2003; Takenoya 
et al., 2008; Takenoya et al., 2010; Motoike et al., 2015) have accumulated to reinforce 
the evidence for a role of NPW as an anorectic peptide. A function of NPW in 
neuroendocrine regulation has been intensively studied. In addition to the prolactin-
releasing activity, intracerebroventricular administration of NPW induced elevated 
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plasma corticosterone or ACTH levels, which were mediated by corticotrophin-releasing 
hormone (Baker et al., 2003; Taylor et al., 2005). These reports suggest that NPW acts as 
a mediator of stress via activation of the hypothalamus-pituitary-adrenal axis. NPW is 
also involved in pain regulation in the spinal cord so that spinally applied NPW produced 
anti-hyperalgesia action in a model of inflammatory pain in rats (Yamamoto et al., 2005). 
In the stomach, NPW is expressed in gastric antral G cells as observed by immunoelectron 
microscopy and is colocalized with a gastric hormone, gastrin (Mondal et al., 2006). 
Although the determination of NPW immunoreactivity within G cells strongly suggests 
that NPW in the stomach may function in an endocrine manner, biological roles of the 
gastric NPW remain to be clarified. Apparent expression of GPR7 and substantial 
projections of NPW fibers in the extended amygdala have drawn attention to the 
involvement of NPW and its receptor in the control of emotion. Phenotypic analyses of 
Gpr7-/- mice in terms of social behavior suggested the link between NPW and the 
regulation of fear and anxiety (Sakurai, 2013). 
Neuropeptide B (NPB), a structurally different peptide from NPW, was simultaneously 
reported as another endogenous ligand for GPR7 and GPR8 by a group in our research 
laboratories in 2002 (Fujii et al., 2002). One year later, two other groups independently 
reported the discovery and analyses of NPW and NPB (Brezillon et al., 2003; Tanaka et 
al., 2003). As a consequence of full deorphanization of both GPR7 and GPR8, the 
International Union of Basic and Clinical Pharmacology officially named GPR7 and 
GPR8, neuropeptides B/W receptor 1 (NPBWR1) and neuropeptides B/W receptor 2 
(NPBWR2), respectively (http://www.iuphar-db.org/nciupharPublications.jsp).  
In conclusion, the author identified NPW, a novel brain-gut peptide that is the 
endogenous ligand for both GPR7 and GPR8 and that affects the central control of feeding 
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behavior and the release of prolactin in rats. This study will provide new insights into the 
physiological roles of NPW and its receptors, GPR7 and GPR8.  
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5. Tables 
 
 
 
 
 
 
 
 
Table 2-1 
Functional activity and binding affinity of human NPW for GPR7 and GPR8 
Human GPR7 Human GPR8
cAMP Binding cAMP Binding
nM nM
NPW23 0.025  0.004 0.096  0.007 0.178  0.007 0.210  0.021
NPW30 0.133  0.034 0.025  0.005 1.244  0.131 0.021  0.002
 
IC50 values for functional activity (nM) were determined by the inhibition of cAMP 
accumulation assay in the presence of forskolin (1 M). IC50 values for binding affinity 
(nM) were determined by the competition binding assay using 125I-labeled human 
NPW23 (80 pM). Results shown are the means  S.E. (n = 3 or 5). 
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Table 2-2 
Quantification of NPW in animal tissues by NPW23- and NPW30-specific two-site 
ELISAs 
*ir-NPW in porcine tissues: each result is a total of the mean of duplicate assays for each 
fraction where the extract of one organ was separated into 40 fractions by reverse phase 
HPLC. 
†ir-NPW in rat tissues and ir-NPW in mouse tissues: each result is the mean of duplicate 
assays for the peptide fraction prepared using octadecyl-bonded silica cartliges.  
‡ND: not detectable. §NA: not available. 
Peptide fractions were obtained from extracts of animal tissues followed by reverse phase 
HPLC for porcine tissues, and by batch absorption and elution using octadecyl-bonded 
silica cartridges for rat and mouse tissues. The peptide fractions as assay samples were 
subjected to the ELISAs to measure immunoreactive NPW (ir-NPW) of 23 and 30 amino 
acid residues.  
 
NPW23 NPW30 NPW23 NPW30 NPW23 NPW30
Whole brain 91 111 13 44 52 2
Spinal cord 72 123 1 9 NA NA
Hypothalamus 282 230 NA NA NA NA
Pituitary 1230 423 32 676 6645 2
Adrenal gland 2 51 NA NA NA NA
Esophagus ND
‡ ND NA NA NA NA
Stomach 55 776 3 88 1 1
Duodenum 31 361 ND ND NA NA
Small intestine ND ND NA NA NA NA
Colon NA
§ NA 1 ND NA NA
Atrium ND ND NA NA NA NA
Heart NA NA ND ND NA NA
Spleen ND ND ND ND NA NA
Pancreas ND ND ND ND NA NA
Liver NA NA ND ND NA NA
Kidney ND ND ND ND NA NA
Ovary ND ND NA NA NA NA
Testis NA NA ND ND NA NA
Thymus ND ND NA NA NA NA
Lung 1 3 ND ND NA NA
ir-NPW in porcine tissues* ir-NPW in rat tissues
†
ir-NPW in mouse tissues
†
(fmole/ 1g wet tissue) (fmole/ 1g wet tissue) (fmole/ 1g wet tissue)
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6. Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2-1. A phylogenetic tree of GPCRs with higher similarity to human GPR7 and 
GPR8. Selected GPCRs presenting amino acid sequence similarity to SLC-1 were 
analyzed by the neighbor-joining method. Bootstrap values are placed on each node. Two 
GPCRs, GPR7 and GPR8, were recognized as orphan GPCRs, and the others were 
GPCRs with known endogenous ligands when the study in Chapter II started. SLC-1, 
melanin-concentrating hormone receptor 1; sst1 receptor, somatostatin receptor 1; sst4 
receptor, somatostatin receptor 4; sst2 receptor, somatostatin receptor 2; sst3 receptor, 
somatostatin receptor 3; sst5, somatostatin receptor 5; NOP receptor, nociceptin receptor; 
 receptor, kappa-type opioid receptor isoform 1;  receptor, delta-type opioid receptor; 
 receptor, mu-type opioid receptor isoform MOR-1. 
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Fig. 2-2.  Gene expression profile of human GPR7 and GPR8. Copy numbers of 
GPR7 and GPR8 mRNA in human tissues were measured by real-time PCR. The gene 
expression in the respective tissues was represented as normalized copy number that was 
calculated as follows: each copy number of GPR7 and GPR8 mRNA was divided by copy 
number of GAPDH mRNA in the same tissue. 
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Fig. 2-3. Isolation of an agonist peptide for human GPR8. A, purification procedure of 
an agonist peptide for human GPR8. The purification procedure comprised two parts of 
process, extraction from the porcine hypothalamus (step 1 to 3) and a combination of 
HPLCs (step 4 to 8). Agonist activity for human GPR8 was monitored with an assay of 
[35S]GTPS binding. B, mechanistic basis of the assay. Once ligand (L) as an agonist for 
human GPR8 binds to the receptor, heterotrimeric G proteins associated with the receptor 
are activated via the changes from GDP- to GTP-bound form, which induces intracellular 
signaling by activating downstream molecules in cells expressing human GPR8. The 
activated state returns to inactivated state through hydrolysis of the GTP to GDP, which 
is catalyzed by  subunit of the G protein. A GTP analogue, [35S]GTPS with highly 
resistant to the GTPase activity of the α subunit remains to bind to the G protein for a 
longer period of time so that an agonist binding to human GPR8 can be detected as an 
increase in radioactivity of [35S]GTPS in the membrane fractions of the cells expressing 
human GPR8. 
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Fig. 2-4. Identification of an endogenous ligand for human GPR8 from the extracts 
of the porcine hypothalamus. A, HPLC profile of the final purification step using the 
Wakosil-II 3C18HG column. The arrow marks the purified material. B, detection of 
[35S]GTPS binding activity to membrane fractions of CHO-GPR8 cells. The eluate was 
manually collected, and the activity was recovered as a single peak with an elution time 
of 29.4 min. 
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Fig. 2-5. Porcine NPW precursor protein cDNA and mature peptide sequences. A 
cDNA clone encoding an agonist peptide for human GPR8 was isolated from a cDNA 
library of the porcine spinal cord. A deduced amino acid sequence of porcine NPW 
precursor protein was obtained from the longest open reading frame of the cDNA. Each 
sequence is placed with the nucleotide sequence above the amino acid sequence. Two Met 
codons as potential translation start site are indicated by boldface letters. The asterisk 
indicates a stop codon. The arrowhead indicates a putative signal peptide cleavage site. 
A pair of basic amino acid residues is boxed. Porcine NPW23 and NPW30 are underlined 
with a solid line and with a broken line, respectively. 
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Fig. 2-6. Activation of human GPR8 by porcine NPW23 and NPW30. A, HPLC 
profiles of synthetic porcine NPW peptides and extracts of the porcine hypothalamus. 
Two arrows mark the elution peaks of the synthetic porcine NPW23 and NPW30 (upper 
panel). The extracts of the porcine hypothalamus were fractionated under the same HPLC 
conditions (lower panel). B, detection of agonist activities in the fractionated extracts of 
the porcine hypothalamus for human GPR8. The agonist activity of each fraction prepared 
from extracts of the porcine hypothalamus was measured by [35S]GTPS binding assay. 
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Fig. 2-7. Human NPW precursor protein cDNA and mature peptide sequences. A 
cDNA clone encoding human NPW precursor protein was isolated from a cDNA library 
of the human hypothalamus. An amino acid sequence was obtained from an open reading 
frame of the cDNA. Each sequence is placed with the nucleotide sequence above the 
amino acid sequence. A putative non-AUG start codon is indicated by boldface letters. 
The asterisk indicates a stop codon. The arrowhead indicates a putative signal peptide 
cleavage site. A pair of basic amino acid residues is boxed. Human NPW23 and NPW30 
are underlined with a solid line and with a broken line, respectively. 
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Fig. 2-8. Expression of NPW peptide produced from human NPW precursor protein 
cDNA with non-AUG start codon. A, purification of an agonist peptide for human GPR8 
from the supernatant of COS-7 cells that were transfected with a human NPW precursor 
protein expression vector. Shown is the HPLC elution profile of the final purification step 
using the SymmetryShield RP18 column. B, detection of an inhibitory effect of the HPLC 
fractions on forskolin-induced cAMP accumulation in CHO-GPR8 cells. The eluate was 
manually collected, and the activity of each fraction was measured by the assay of cAMP 
accumulation inhibition using CHO-GPR8 cells in the presence of forskolin (1M). The 
activity was recovered as a single peak with an elution time of 105.5 min. 
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Fig. 2-9. Rat NPW precursor protein cDNA and mature peptide sequences. A cDNA 
clone encoding rat NPW precursor protein was isolated from a cDNA library of the rat 
brain. A deduced amino acid sequence of rat NPW precursor protein was obtained from 
the longest open reading frame of the cDNA. Each sequence is placed with the nucleotide 
sequence above the amino acid sequence. One Met codon as potential translation start site 
is indicated by boldface letters. The asterisk indicates a stop codon. The arrowhead 
indicates a putative signal peptide cleavage site. A pair of basic amino acid residues is 
boxed. Rat NPW23 and NPW30 are underlined with a solid line and with a broken line, 
respectively. 
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Fig. 2-10. Mouse NPW precursor protein cDNA and mature peptide sequences. A 
cDNA clone encoding mouse NPW precursor protein was isolated from a cDNA library 
of the mouse brain. An amino acid sequence was obtained from an open reading frame of 
the cDNA. Each sequence is placed with the nucleotide sequence above the amino acid 
sequence. A putative non-AUG start codon is indicated by boldface letters. The asterisk 
indicates a stop codon. The arrowhead indicates a putative signal peptide cleavage site. 
A pair of basic amino acid residues is boxed. Mouse NPW23 and NPW30 are underlined 
with a solid line and with a broken line, respectively. 
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NPW23
Rat W Y K H V A S P R Y H T V G R A S G L L M G L
Mouse W Y K H V A S P R Y H T V G R A S G L L M G L
Human W Y K H V A S P R Y H T V G R A A G L L M G L
Pig W Y K H T A S P R Y H T V G R A A G L L M G L
NPW30
Rat W Y K H V A S P R Y H T V G R A S G L L M G L R R S P Y L W
Mouse W Y K H V A S P R Y H T V G R A S G L L M G L R R S P Y Q W
Human W Y K H V A S P R Y H T V G R A A G L L M G L R R S P Y L W
Pig W Y K H T A S P R Y H T V G R A A G L L M G L R R S P Y M W  
 
Fig. 2-11. Comparison of mature NPW23 and NPW30 amino acid sequences among 
humans, pigs, rats, and mice. Human, porcine, rat, and mouse NPW23 and NPW30 
sequences were aligned with each other. The amino acid residues identical among the four 
species are shaded in black. 
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Fig. 2-12. Comparison of NPW precursor proteins among humans, pigs, rats, and 
mice. Deduced NPW precursor proteins were aligned with each other using CLUSTAL 
W multiple sequence alignment. Human and mouse NPW precursor proteins were 
presumed to undergo translation from non-AUG start codons, while porcine and rat NPW 
precursor proteins were predicted to be translated from AUG start codons. Among them, 
the asterisk indicates an identical amino acid in the precursor proteins, and the amino acid 
residues are written in red or blue. A putative signal peptide sequence with hydrophobic 
amino acid cluster preceding the mature NPW peptides is boxed in blue. The NPW30 
sequence is boxed in black. Two pairs of basic amino acid residues, Arg-Arg, are written 
in blue.  
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Fig. 2-13. Functional and binding characterization of NPW. A and B, dose-dependent 
inhibition of cAMP accumulation by NPW in CHO-GPR7 and CHO-GPR8 cells, 
respectively. Various concentrations of NPW23 or NPW30 were added to CHO-GPR7 
and CHO-GPR8 cells, and cAMP accumulation inhibition assay was conducted in the 
presence of forskolin (1 M). ■, human NPW23; ▲, human NPW30. C and D, effect of 
pertussis toxin on the NPW activation of CHO-GPR7 and CHO-GPR8 cells, respectively. 
CHO-GPR7 or CHO-GPR8 cells were treated with or without pertussis toxin (PTX; 100 
ng/ml) for 24 h. After washing these cells, the inhibitory effect of human NPW23 (1 nM) 
on cAMP accumulation induced by forskolin (1 M) was analyzed. E and F, saturation 
binding between 125I-labeled human NPW23 and CHO-GPR7 cells and between 125I-
labeled human NPW23 and CHO-GPR8 cells, respectively. ●, total binding; ○, specific 
binding; ■, nonspecific binding. Insets, Scatchard analysis of the radioligand binding. 
Results shown are the means of triplicate experiments. 
  
A 
B 
C 
D 
E 
F 
 83 
 
 
 
 
 
 
 
 
 
Fig. 2-14. Two different ELISAs for quantification of NPW23 and NPW30. A and B, 
standard curve of each NPW peptide in NPW23 ELISA and NPW30 ELISA, respectively. 
Various concentrations of synthetic NPW23 and NPW30 of human, porcine, rat, and 
mouse sequences were subjected to the ELISAs, and the NPW23 and NPW30 peptides 
captured on the ELISA assay plates were detected. ●, human NPW23; ▲, porcine 
NPW23; ■, rat NPW23; ⧫, mouse NPW23; ○, human NPW30; △, porcine NPW30; □, rat 
NPW30; ◊, mouse NPW30.  
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Fig. 2-15. In vivo effects of NPW in rats. A, increase of food intake by 
intracerebroventricular administration of human NPW23 in rats. After injection at 15:00, 
food intake was measured. Cumulative food consumption was plotted over a 2-h period. 
●, 10 nmol of NPW23; ▲, vehicle. Results shown are the means  S.E. (n = 10). 
Statistical comparisons were performed using Student’s t test. *, p  0.05; **, p  0.01. 
B, stimulation of prolactin release by intracerebroventricular administration of human 
NPW23 in rats. After injection at 13:00, blood samples were collected, and the 
concentration of prolactin in the plasma samples was determined. ●, 3 nmol of NPW23; 
▲, vehicle. Results shown are the means  S.E. (n = 9 or 10). Statistical comparisons 
were performed using Student’s t test. *, p  0.05. 
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General Conclusion 
 
The results obtained in this study were acquired by focusing on the analysis of the 
molecular nature of two pairs of deorphanized GPCRs and their endogenous ligands. The 
discovery of SLC-1 as a functional MCH receptor enables the understanding of a variety 
of MCH functions in the CNS as collective responses of the neural networks containing 
SLC-1 positive neurons. In addition, the pairing of SLC-1 with MCH is expected to 
accelerate research and development of the MCH receptor antagonists with better 
pharmacological profile for the treatment of obesity, anxiety, or sleep disorders. The 
discovery of NPW, a novel brain-gut peptide as the endogenous ligand for GPR7 and 
GPR8 paved the way for the field of NPW biology. The selective localization of NPW 
peptide and preferential gene expression of its receptors, GPR7 and GPR8, in the brain 
triggered studies on biological roles of NPW in the CNS. It is expected that the 
significance of the pathophysiological roles of NPW will be elucidated by taking 
advantage of the initial knowledge and basic technologies on NPW, which were provided 
by the efforts in this study.  
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